0001104659-20-125523.txt : 20201116 0001104659-20-125523.hdr.sgml : 20201116 20201116100128 ACCESSION NUMBER: 0001104659-20-125523 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anchiano Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 201314306 BUSINESS ADDRESS: STREET 1: 5 KIRYAT HAMADA ST STREET 2: PO BOX 45032 CITY: JERUSALEM STATE: L3 ZIP: 9777401 BUSINESS PHONE: 972-2-5486555 MAIL ADDRESS: STREET 1: 5 KIRYAT HAMADA ST STREET 2: PO BOX 45032 CITY: JERUSALEM STATE: L3 ZIP: 9777401 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 10-Q 1 tm2029629d1_10q.htm FORM 10-Q

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, DC 20549

 

 

 

FORM 10-Q

 

 

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File Number: 001-38807

 

 

 

Anchiano Therapeutics Ltd. 

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Israel   81-3676773

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

One Kendall Square

Building 1400E

Suite 14-105

Cambridge, MA 02139

(Address of principal executive offices including zip code)

 

Registrant’s telephone number, including area code: (857) 259-4622

 

 

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
American Depositary Shares, each representing five ordinary shares, no par value per share ANCN Nasdaq Capital Market
Ordinary shares, no par value per share n/a Nasdaq Capital Market*

 

*Not for trading; only in connection with the registration of American Depository Shares

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer     ¨   Accelerated filer   ¨
Non-accelerated filer   x   Smaller reporting company   x
        Emerging growth company   x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

As of November 16, 2020, the registrant had 37,099,352 ordinary shares outstanding.

 

 

 

 

 

 

ANCHIANO THERAPEUTICS LTD.

 

QUARTERLY REPORT ON FORM 10-Q 

FOR THE QUARTER ENDED SEPTEMBER 30, 2020

 

TABLE OF CONTENTS

 

Page

 

PART I. – FINANCIAL INFORMATION 2
   
Item 1. Financial Statements 2
   
  Condensed Consolidated Balance Sheets as of September 30, 2020 and December31, 2019 2
   
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the Nine Months Ended September 30, 2020 and 2019 3
   
  Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Nine Months Ended September 30, 2020 and 2019 4
   
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019 5
   
  Notes to Condensed Consolidated Financial Statements 6
   
Item 2.          MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 13
   
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 19
   
Item 4. Controls and Procedures. 19
   
PART II. – OTHER INFORMATION 20
   
Item 1. Legal Proceedings 20
   
Item 1A. Risk Factors 20
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 22
   
Item 3. Defaults Upon Senior Securities. 22
   
Item 4. Mine Safety Disclosures. 22
   
Item 5. Other Information. 22
   
Item 6. Exhibits. 22
   
SIGNATURES 23

 

-i-

 

 

NOTE ABOUT FORWARD-LOOKING STATEMENTS

 

This quarterly report contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Quarterly Report on Form 10-Q. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, but these are not the only ways these statements are identified. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.

 

As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires:

 

  · references to “Anchiano Therapeutics Ltd.” “Anchiano,” the “Company,” “us,” “we” and “our” refer to Anchiano Therapeutics Ltd. an Israeli company and its consolidated subsidiaries;

 

  · references to “ordinary shares,” “our shares” and similar expressions refer to the Company’s ordinary shares, no nominal (par) value;

 

  · references to “ADS” refer to the American Depositary Shares listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN,” each representing five ordinary shares of the Company;

 

  · references to “dollars,” “U.S. dollars” and “$” are to U.S. Dollars;

 

  · references to “NIS” are to New Israeli Shekels; and

 

  · references to the “SEC” are to the U.S. Securities and Exchange Commission.

 

1

 

 

PART I. – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019

 

ANCHIANO THERAPEUTICS LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except share and per share data)

 

    September 30,     December 31,  
    2020     2019  
ASSETS                
Current assets:                
Cash and cash equivalents   $ 6,768     $ 17,575  
Prepaid expenses and other     620       636  
Total current assets     7,388       18,211  
                 
Property and equipment, net     15       158  
Operating lease right-of-use     234       1,199  
Other non-current assets     52       187  
Total assets   $ 7,689     $ 19,755  
                 
LIABILITIES AND SHAREHOLDERS' EQUITY                
Current liabilities:                
Trade payables   $ 482     $ 875  
Accrued expenses and other     1,620       2,855  
Operating lease liability     173       391  
Total current liabilities     2,275       4,121  
                 
Non-current operating lease liability     63       725  
Total liabilities     2,338       4,846  
                 
Commitments and contingencies                
                 
Shareholders' equity:                
Ordinary shares, no par value - authorized 500,000,000 shares as of  September 30, 2020 and 100,000,000 shares as of December 31,2019; issued and outstanding 37,099,352 shares at September 30, 2020 and December 31,2019     -       -  
Paid-in capital     119,375       119,468  
Currency translation differences reserve     872       872  
Accumulated deficit     (114,896 )     (105,431 )
Total shareholders' equity     5,351       14,909  
Total liabilities and shareholders' equity   $ 7,689     $ 19,755  

 

See accompanying notes to unaudited condensed consolidated financial statements

 

2

 

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Nine Months Ended September 30, 2020 and 2019

 

ANCHIANO THERAPEUTICS LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited, in thousands, except share and per share data)

 

   Three months ended September 30,   Nine months ended September 30, 
   2020    2019   2020   2019 
Operating expenses:                     
Research and development  $1,252    $5,565   $3,609   $12,276 
General and administrative   1,125     1,705    5,126    4,958 
Restructuring expense   79     -    749    - 
Total operating expenses   2,456     7,270    9,484    17,234 
                      
Finance (income) expense, net   (7 )   (102)   (19)   4,286 
                      
Net loss and comprehensive loss  $(2,449 )  $(7,168)  $(9,465)  $(21,520)
                      
Basic and diluted loss per share  $(0.07 )  $(0.19)  $(0.26)  $(0.64)
                      
Weighted average number of shares outstanding - basic and diluted   37,099,352     37,099,352    37,099,352    33,551,494 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3

 

 

Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Nine Months Ended September 30, 2020 and 2019

 

ANCHIANO THERAPEUTICS LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Unaudited, in thousands, except share data)

 

               Currency         
   Ordinary shares       translation         
   Number of   Amounts   Paid-in   differences   Accumulated     
   shares   (*)   capital   reserve   deficit   Total 
Balance at January 1, 2020   37,099,352   $-   $119,468   $872   $(105,431)  $14,909 
Share-based compensation   -    -    264    -    -    264 
Net loss   -    -    -    -    (7,016)   (7,016)
Balance at June 30, 2020   37,099,352    -    119,732    872    (112,447)   8,157 
Share-based compensation   -    -    (357)   -    -    (357)
Net loss   -    -    -    -    (2,449)   (2,449)
Balance at September 30, 2020  $37,099,352   $-   $119,375   $872   $(114,896)  $5,351 
                               
Balance at January 1, 2019   15,575,682   $-   $87,240   $872   $(78,307)  $9,805 
Issuance of shares, net   21,523,670    -    26,500    -    -    26,500 
Reclassification of warrants due to reassessment   -    -    (3,628)   -    -    (3,628)
Reclassification of warrants due to modification   -    -    8,198    -    -    8,198 
Share-based compensation   -    -    748    -    -    748 
Net loss   -    -    -    -    (14,374)   (14,374)
Balance at June 30, 2019   37,099,352    -    119,058    872    (92,681)   27,249 
Share-based compensation   -    -    321    -    -    321 
Net loss   -    -    -    -    (7,168)   (7,168)
Balance at September 30, 2019   37,099,352   $-   $119,379   $872   $(99,849)  $20,402 
                               
(*) No par value                              

 

(*) No par value

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

4

 

 

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019

 

ANCHIANO THERAPEUTICS LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)

 

   Nine months ended September 30, 
   2020   2019 
Operating activities:          
Net loss  $(9,465)  $(21,520)
Adjustments required to reconcile net loss to net cash used in operating activities:          
Financing costs, net   -    4,652 
Depreciation   77    70 
Gain on sale of property and equipment   (19)   - 
Share-based payments   (93)   1,069 
Write-off of right-of-use related to restructuring   85    - 
Changes in operating asset and liabilities:          
Prepaid and other current   16    4,823 
Other non-current assets   5    70 
Trade payables   (393)   913 
Accrued expenses and other   (1,235)   (621)
Net cash used in operating activities   (11,022)   (10,544)
           
Investing activities:          
Purchase of property and equipment   (34)   (346)
Proceeds from sale of property and equipment   119    - 
Net cash provided by (used in) investing activities   85    (346)
           
Financing activities:          
Proceeds from issuance of ordinary shares and warrants   -    30,500 
Issuance costs   -    (3,879)
Net cash provided by financing activities   -    26,621 
           
Increase (decrease) in cash, cash equivalents and restricted cash   (10,937)   15,731 
Cash, cash equivalents and restricted cash at, beginning of period   17,705    7,640 
Cash, cash equivalents and restricted cash at, end of period  $6,768   $23,371 
           
Reconciliation in amounts on consolidated balance sheets:          
Cash and cash equivalents  $6,768   $23,241 
Restricted cash   -    130 
Total cash, cash equivalents and restricted cash  $6,768   $23,371 
           
Supplemental disclosure of cash flow information:          
Reclassification of warrants due to reassessment  $-   $3,628 
Reclassification of warrants due to modification  $-   $8,198 
Taxes paid in cash  $-   $605 
Interest paid in cash  $-   $4 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

5

 

 

Notes to Condensed Consolidated Financial Statements

 

1. The Company and Basis of Presentation

 

Anchiano Therapeutics Ltd. is an early-stage preclinical biopharmaceutical company committed to discovering and developing new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies. The Company is developing small-molecule pan-mutant RAS inhibitors and inhibitors of PDE10 and the β-catenin pathway.

 

In November 2019, the Company discontinued clinical development of inodiftagene vixteplasmid. After a thorough evaluation of the available data, the Company determined there was a low probability of surpassing the pre-defined futility threshold at the planned interim analysis of its Phase 2 Codex study, which was evaluating inodiftagene vixteplasmid in patients with BCG-unresponsive non-muscle-invasive bladder cancer (“NMIBC”), and announced the discontinuation of the study.

 

In January 2020, the Board of Directors of the Company approved management’s recommendation to close the Company’s office and laboratories located in Israel. Following the closure of the Israeli facilities at the end of May 2020, the Company’s sole remaining office is located in Cambridge, Massachusetts (for details, see Note 4 below). The Company currently maintains the lease on this facility in good standing and is also assessing the ability of the staff to continue working remotely under the restrictions of COVID-19.

 

In March 2020 the World Health Organization declared the global novel coronavirus (COVID-19) outbreak a pandemic. As of October 14, 2020, the Company’s operations have not been significantly impacted by the COVID-19 outbreak. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned pre-clinical development activities.

 

On July 2, 2020, the Company’s Chief Executive Officer Dr. Frank Haluska sent a letter to the Company’s Chairman outlining Dr. Haluska’s belief that events had occurred that were sufficient to trigger his ability to resign for “Good Reason” under his employment agreement. The Board informed Dr. Haluska that it disagreed with the letter’s assertions regarding “Good Reason” and treated the letter as a constructive resignation effective as of July 2, 2020. On July 12, 2020, Dr. Frank Haluska tendered his written resignation from the Company’s Board of Directors, effective immediately. Dr. Haluska referenced the matters articulated in his letter of July 2, 2020, and the Company’s response and actions following receipt of the letter as the basis for his resignation from the Board. It is the Company’s position, based on its legal counsel, that the CEO resigned without Good Reason, is not entitled to severance, and the Company will contest any and all claims for severance. Prior to the appointment of Mr. Neil Cohen as CEO in October 2020 (see below) the Board handled all matters related to CEO duties.

 

On October 20, 2020, the Company appointed Mr. Neil Cohen as Chief Executive Officer of the Company, effective immediately. Mr. Cohen will continue to serve as a member of the Company’s board of directors. The Company also appointed Andrew Fine to serve as the Chief Financial Officer of the Company, effective immediately. Mr. Fine previously served as the Company’s Interim Chief Financial Officer pursuant to a subcontracting agreement.

 

In light of business circumstances, and in order to conserve cash and preserve optionality while alternatives are being identified and assessed, the Company made a decision during July 2020 to undertake reductions in headcount and other cost saving measures. These include plans to temporarily reduce its internal and external research and development work on the Company’s pan-RAS-inhibitor program until there is greater clarity regarding Anchiano’s ability to fund the program. The Company continues to undertake actions for the promotion of the program and its assets and towards strengthening the protection of all related intellectual property.

 

As a result of the above the Company took charges associated with severance and, discontinuation of external clinical development activities,. These charges amounted to $1.03 million for discontinuation of external clinical development activities and $0.5 million for severance (see Notes 6 and 7 below).

 

The Company is incorporated and registered in Israel. The Company's American Depositary Shares ("ADSs"), each representing five ordinary shares of the Company with no par value (the "ordinary shares"), began trading on the Nasdaq Capital Market (“Nasdaq”) in February 2019 under the symbol "ANCN". The Company’s ordinary shares traded on the Tel Aviv Stock Exchange (“TASE”) between August 2006 and June 2019, at which time the Company voluntarily delisted from the TASE. The Company wholly owns a subsidiary, Anchiano Therapeutics Israel Ltd., which itself wholly owns a Delaware-incorporated subsidiary, Anchiano Therapeutics, Inc.

 

6

 

 

Liquidity

 

The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company has incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit at September 30, 2020 of $114.9 million. The Company has financed operations to date primarily through public and private placements of equity securities. The Company anticipates that it will continue to incur net losses for the foreseeable future. The Company believes that its existing cash and cash equivalents will only be sufficient to fund its projected cash needs into the first quarter of 2021. Accordingly, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. To meet future capital needs, the Company would need to raise additional capital through equity or debt financing or other strategic transactions. However, any such financing may not be on favorable terms or may not be available to the Company on any terms. The failure of the Company to obtain sufficient funds on commercially-acceptable terms when needed, would have a material adverse effect on the Company’s business, results of operations and financial condition. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of the Company’s expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company’s expenses could prove to be significantly higher than it currently anticipates. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Unaudited Interim Financial Information

 

The interim condensed consolidated financial statements included in this quarterly report are unaudited. The unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of September 30, 2020, and its results of operations for the three and nine months ended September 30, 2020 and 2019, changes in shareholders’ equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other future annual or interim period. The December 31, 2019 balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Form 10-K for the year ended December 31, 2019 as filed with the SEC. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2019 included in the Company’s Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.

 

2. Summary of Significant Accounting Policies

 

a. Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis, including those related to share-based compensation, leases and derivatives. The Company's management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

 

b. Reclassifications

 

Certain prior year amounts shown in the accompanying unaudited condensed consolidated financial statements have been reclassified to conform to the 2020 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total shareholders’ equity, net loss, or loss per share.

 

7

 

 

 

3. Accrued expenses and other

 

Accrued and other current liabilities consist of the following for the periods indicated (in thousands):

 

   September 30,   December 31, 
   2020   2019 
Accrued expenses  $1,361   $372 
Restructuring accrual   238    2,161 
Payroll and related   21    60 
Liability for employee rights upon retirement   -    262 
   $1,620   $2,855 

 

4. Leases

 

In January 2018, the Company signed an agreement to rent a laboratory and offices in Jerusalem through May 2023. The Company had an option to extend the agreement by another five years. The annual rent (including management fees) is approximately $0.4 million and is linked to the Israeli Consumer Price Index. Pursuant to the agreement, bank guarantees of $0.1 million were provided to the property owner. In January 2020, pursuant to the Company’s decision to close its Israeli operations, the agreement was modified such that the Company vacated the facilities on May 30, 2020 but will continue to make scheduled lease payments through October 31, 2020. The Company recorded restructuring expense of $247,000 related to the modification of the Israeli lease agreement and settled all obligations associated with the lease.

 

In May 2018, the Company signed an agreement to rent space for its headquarter offices in Cambridge, Massachusetts. This agreement was amended in October 2019 to reflect relocating to a new 2,400 square foot suite within the same facility effective February 1, 2020. The annual rent is approximately $0.2 million. The amended lease term ends January 31, 2022 and there are no options to extend the lease.

 

The Company currently maintains the lease in good standing and is assessing the ability of the staff to continue working remotely under the restrictions of COVID-19. .

 

5. License Agreement

 

In September 2019, the Company announced that it entered into an option to license agreement with ADT Pharmaceuticals, LLC (“ADT”). Pursuant to the terms and conditions set forth in the agreement, the parties agreed to conduct research and development activities of novel small-molecule inhibitors (RAS and PDE10/β-catenin). As part of the arrangement, the Company is primarily responsible for the research, development, manufacturing and regulatory activities and ADT assists with the research activities as necessary in exchange for a quarterly fee from the Company. In connection with the agreement, ADT also granted the Company exclusive rights to research, develop, manufacture and commercialize the aforementioned compounds relating to patents owned by ADT and any products containing such compounds worldwide. In consideration for the rights granted under the agreement, the Company committed to pay ADT (i) a $3 million upfront fee; (ii) a fee upon transfer of the know-how and intellectual property rights to the Company; and then (iii) additional payments, including milestone and royalty payments. The Company has the ability to terminate the agreement at any time in its entirety or on a compound-by-compound basis after providing 90 days written notice to ADT. The upfront fee was paid in the third quarter of 2019. The Company accounted for the upfront fee and additional payments as a research and development expenses and continues to make ongoing payments to ADT in support of its maintenance of the Company’s assets.

 

In April 2020, the Company notified Yissum Technology Transfer Company of the Hebrew University Ltd. (“Yissum”) that as a result of the Company’s previous decision to discontinue clinical development of inodiftagene, it will cease payments to maintain intellectual property (“IP”) it licensed from Yissum that supported the development and as related to a licensing and development agreement between the parties (“License Agreement”). In August 2020 the Company agreed with Yissum on termination of the License Agreement, the Company destroyed or returned all IP documentation to Yissum and Yissum and the Company mutually waived, released and discharged the other from all claims of any type.

 

8

 

 

6. Restructuring

 

Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication has been made to those affected.

 

The Company has recorded restructuring expenses related principally to contract termination costs due to the discontinuation of the clinical trials to CROs and manufacturers and contractual involuntary termination benefits to employees which have been accounted for as ongoing benefit arrangements and associated termination costs related to the reduction of its workforce.

 

One-time termination benefits are expensed at the date the employees are notified, unless the employees must provide future services beyond a minimum retention period, in which case the benefits are expensed ratably over the future service periods. A provision for contract termination costs, in which a contract is terminated or the entity will continue to incur costs pursuant to contract for its remaining term without economic benefit, is recognized only when the contract is terminated or when the entity permanently ceases using the rights granted under the contract.

 

In November 2019, the Company decided to discontinue its Phase 2 Codex study in patients with BCG-unresponsive NMIBC. In connection with this decision, the Company is required to make certain payments under contracts with CROs and with manufactures of the drug in order to terminate the contracts and close the trials. This restructuring plan included a reduction in the workforce of seven employees.

 

In January 2020, the Board of Directors approved management’s recommendation to close the Company’s office and laboratories located in Israel. In connection with this restructuring, the employment of the remaining five Israeli employees was terminated in the second quarter of 2020.

 

As noted above, in conjunction with this decision the Company renegotiated its lease for Israeli laboratory and office space. In connection with this decision, the Company vacated the facilities on May 31, 2020 but will continue to make scheduled lease payments through October 31, 2020. In the first quarter of 2020, the Company recorded a restructuring charge to adjust its operating lease right of use asset and operating lease liability to reflect the loss on the early termination of the Israeli lease obligation.

 

The following table represents a roll forward of the restructuring and other activities noted above (in thousands):

 

    CRO,
Manufacturing
and other related
    Severance-
related
    Facility
and
Leases
    Total  
Balance, January 1, 2020   $ 2,572     $ 336     $ -     $ 2,908  
Expenses     502       -       247       749  
Paid or consumed     (2,835 )     (336 )     (247 )     (3,138 )
Balance, September 30, 2020   $ 238     $ -     $ -     $ 238  

 

7. Research and development

 

As noted above, and in conjunction with the Company’s decision to reassess its strategy around research and development efforts of its scientific and assets, in the third quarter the Company took charges associated with severance and, discontinuation of clinical development activities,. These charges amounted to $1.03 million for discontinuation of clinical development activities and $0.5 million for severance of research and development personnel.

 

8. Shareholders’ Equity

 

a. 2018 Private Placement

 

In June 2018, the Company completed a $22.9 million fundraising round from investors in the United States and Israel. In consideration for the investment, the Company issued 5,960,787 ordinary shares at a price per share of approximately $3.842, as well as 2,713,159 warrants to acquire additional shares equal to 80% of the shares issued, at an exercise price per share of NIS 16.20 (approximately $4.32). The warrants are exercisable for five years from December 31, 2018, the closing date of the transaction, and may be exercised on a cashless basis.

 

9

 

 

In addition, the investors were granted price protection rights (to shares and warrants) in the event of a future share issuance by the Company wherein the price does not increase by at least approximately 42.86% over the price per share in the fundraising (or is less than the adjusted price per share, if the price has already been adjusted). For details of an allocation that took place in 2019 pursuant to these rights, see Note 7b below. The warrants and shares were recorded within equity on the issuance date.

 

Effective January 1, 2019, the Company changed its functional currency from NIS to USD. Due to this change, the exercise price of the warrants was no longer denominated in the Company’s functional currency and therefore not considered indexed to the Company’s own shares according to ASC 815-40.  Accordingly, the Company recorded the fair value of the warrants as a liability at January 1, 2019.

 

Subsequently, upon the Company’s Nasdaq initial public offering on February 14, 2019, the warrants’ term was modified such that the exercise price currency was changed to USD. As a result, the warrants were once again considered indexed to the Company’s own shares according to ASC 815-40. Accordingly, the fair value of the warrants at February 14, 2019 was reclassified from a liability to equity on that date.

 

The following table summarizes the activity for the warrants whose fair value measurements are estimated utilizing Level 3 inputs:

 

   2019 
Fair value on January 1, 2019  $3,628 
Adjustments-finance expenses   4,570 
Fair value on February 14, 2019  $8,198 

 

The Company has determined the fair value of the warrants (a Level 3 valuation) as of January 1, 2019 and February 14, 2019. The fair value of these warrants was estimated by implementing the Probability-Weighted Expected Return Method or the Black-Scholes Method. The following parameters were used:

 

   Derivative Financial
Instrument
 
   February 14,
2019
   January 1,
2019
 
Share  price  $1.84   $2.50 
Expected term   End of 2022    End of 2022 
Risk free rate   2.49%   1.37%
Volatility   52%   48%

 

b. Public Offering

 

On February 14, 2019, the Company raised gross proceeds of $30.5 million in its Nasdaq initial public offering (“IPO”), allocating 2,652,174 ADSs, each representing five ordinary shares of the Company. The ADSs are listed under the symbol “ANCN.” In accordance with price protection rights granted in 2018 and activated in the offering (see Note 7a above for details and accounting treatment), the Company issued an additional 8,262,800 ordinary shares (equivalent to 1,652,560 ADSs) to rights holders and adjusted their warrants to be exercisable for an additional 6,207,330 ordinary shares (equivalent to 1,241,466 ADSs).

 

c. Share-based compensation

 

The Company has two share-based compensation plans under which share options or other share-based awards have been granted: the 2011 Share Option Plan and the 2017 Share Option Plan (the “2017 Plan”). The 2017 Plan replaced the 2011 Share Option Plan with respect to future grants; and, therefore, no further awards may be made under 2011 Share Option Plan. The Compensation Committee of the Board of Directors and the Board of Directors administer these plans.

 

10

 

 

The fair value of each option granted is estimated using the Black-Scholes option pricing method. The volatility is based on the Company’s historical volatility. The risk-free interest rate assumption is based on observed Treasury yields over the expected term of the options granted with USD-denominated exercise prices (options granted in the past with NIS-denominated exercise prices used the equivalent Israeli government bond yields). The Company’s management uses the mid-point between the vesting date and the contractual term for each vesting tranche or its expectations, as applicable, of each option as its expected term. The expected term of the options granted represents the period of time that granted options are expected to remain outstanding

 

The fair value of each option granted in the nine months ended September 30, 2019 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:

 

   Nine months ended 
   September 30, 2019 
Value of ordinary share  $1.03 - $1.54 
Dividend yield   0%
Expected volatility   51.5% - 68.6% 
Risk-free interest rate   2.2% - 2.5% 
Expected term (years)   5.5 - 6.9 

 

The fair value of each option granted in the nine months ended September 30, 2020 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:

 

   Nine months ended 
   September 30, 2020 
Value of ordinary share  $0.15 - $0.17 
Dividend yield   0%
Expected volatility   64.9% - 67.4% 
Risk-free interest rate   0.30% to 0.39% 
Expected term (years)   5.5 - 6.5 

 

The following table summarizes the number of options outstanding and exercisable as of September 30, 2020:

 

    Number of
Shares
   Weighted
Average
Exercise Price
   Weighted Average
Remaining
Contractual Life in
Years
 
Options outstanding - January 1, 2020    3,822,374   $2.50    8.5 
Granted    885,000           
Forfeited/expired/cancelled    (1,578,031)          
Options outstanding - September 30, 2020    3,129,343   $2.44    7.9 
Options exercisable - September 30, 2020    2,389,840   $3.01    7.5 

 

The aggregate intrinsic value of both outstanding and exercisable options at September 30, 2020 is $0.

 

11

 

 

The following table illustrates the effect of share-based compensation on the statements of operations (in thousands):

 

   Three months ended   Nine months ended 
   September 30,   September 30, 
   2020   2019   2020   2019 
Research and development  $(290)  $154   $(166)  $438 
General and administrative   (67)   168    70    632 
   $(357)  $322   $(96)  $1,070 

 

The negative amounts for both Research and development and General and administrative reflect the forfeiture of vested stock options and the reversal of accrued compensation on account of future vesting on stock options that were granted to employees who were terminated as part of the Company’s restructuring activities as mentioned above.

 

9. Net Loss per share

 

Basic loss per share is computed on the basis of the net loss for the period divided by the weighted-average number of ordinary shares outstanding during the period. Diluted loss per share is based upon the weighted-average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options which are included under the treasury stock method when dilutive.

 

The following ordinary shares underlying stock options and warrants were excluded from the calculation of diluted net loss per ordinary share, because their effect would have been anti-dilutive for the three and nine month periods presented:

 

   September 30 
   2020   2019 
Stock Options   3,129,343    3,985,858 
Warrants   10,975,959    10,975,959 

 

12

 

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Overview

 

We are a preclinical biotechnology company committed to discovering and developing new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies. Throughout most of 2019, we ran a Phase 2 study, designated Codex, evaluating inodiftagene vixtepasmid in patients with BCG-unresponsive NMIBC. However, in November 2019, after a thorough evaluation of data, we determined there was a low probability of surpassing the pre-defined futility threshold at the planned interim analysis of the study, and announced the discontinuation of the study and of active clinical development of inodiftagene vixtepasmid.

 

On September 13, 2019, we entered into a Collaboration and License Agreement (the “License Agreement”) with ADT Pharmaceuticals, LLV (“ADT”), pursuant to which we acquired the rights to two small molecule developmental programs targeting oncogenic pathways, focused on pan-mutant RAS inhibitors (our “pan-RAS-inhibitor program”) and inhibitors of PDE10 and the β-catenin pathway, respectively. Under the License Agreement, we are primarily responsible for the research, development, manufacturing, regulatory and commercial activities with respect to the compounds conveyed and contemplated thereunder. Our operations are focused on the successful development, regulatory approval and commercialization of products derived from such compounds.

 

Since entering into the License Agreement, we have focused our efforts on the development of our pan-RAS-inhibitor program. In order to advance this program, our management had been working to identify additional financing sources and/or potential co-development partners. Such efforts, however, have not resulted in opportunities that are sufficiently mature to date. As a result, we decided to undertake certain cost-saving measures, including a workforce reduction and temporary reduction of our internal and external research and development activities with respect to our pan-RAS-inhibitor program, in order to conserve cash and preserve optionality while alternatives are being identified and assessed. We continue to maintain and support the development of our rights in the program including the License Agreement with ADT (see below) and intellectual property protection activities. The workforce reduction included 3 employees, which represented approximately 60% of our workforce as of June 30, 2020, and was completed in the 3rd quarter of 2020. We incurred severance related charges of $0.5 million in the third quarter as well as $0.9 million in other costs due to events associated with or resulting from our research and development workforce reduction and refocus in relation to external development activities.

 

We have also engaged Oppenheimer & Co. to act as our financial advisor to review strategic alternatives focused on maximizing shareholder value. Despite undertaking this process, we may not be successful in completing a transaction, and, even if a strategic transaction is completed, it ultimately may not deliver the anticipated benefits or enhance shareholder value.

 

Our corporate structure consists of a parent company, Anchiano Therapeutics Ltd., incorporated in Israel, which wholly owns a subsidiary, Anchiano Therapeutics Israel Ltd, incorporated in Israel, which itself wholly owns a subsidiary, Anchiano Therapeutics, Inc. incorporated in Delaware. We currently maintain offices in Cambridge, Massachusetts.

 

13

 

 

License Agreement

 

In September 2019, we publicly announced that we had entered into the License Agreement with ADT. Pursuant to the terms and conditions set forth in the License Agreement, we mutually agreed to use commercially reasonable efforts to conduct research and development activities of novel small-molecule inhibitors (RAS and PDE10/β-catenin). As part of the arrangement, we are primarily responsible for the research, development, manufacturing and regulatory activities and ADT will assist with the research activities as necessary in exchange for a quarterly fee. In connection with the License Agreement, ADT also granted us exclusive rights to research, develop, manufacture and commercialize the aforementioned compounds relating to patents owned by ADT and any products containing such compounds worldwide. In consideration for the rights granted under the License Agreement, we paid ADT a $3 million upfront fee in 2019, and agreed to pay to ADT (i) a fee upon transfer of the know-how and intellectual property rights to us; and (ii) additional payments, including milestone and royalty payments. We have the ability to terminate the License Agreement at any time in its entirety or on a compound-by-compound basis after providing 90 days written notice to ADT. Since there is no alternative future use for the upfront fee, we accounted for it as a research and development expense.

 

In April 2020, we notified Yissum Technology Transfer Company of the Hebrew University Ltd. (“Yissum”) that as a result of our previous decision to discontinue clinical development of inodiftagene, we will cease payments to maintain intellectual property ("IP") we licensed from Yissum under the licensing and development agreement between the parties (“License Agreement”). In August 2020 we agreed with Yissum on termination of the License Agreement, we destroyed or returned all IP documentation to Yissum and we and Yissum mutually waived, released and discharged each other from all claims of any type..

 

Components of Operating Results

 

Revenues

 

To date, we have not generated any revenue. We do not expect to receive any revenue unless and until we obtain regulatory approval and commercialize a future product candidate, or until we receive revenue from a collaboration such as a co-development or out-licensing agreement. There can be no assurance that we will receive such regulatory approvals, and if a future product candidate is approved, that we will be successful in commercializing it.

 

Research and Development Expenses

 

Research and development activities are our primary focus. Due to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with certainty the costs we will incur and the timelines that will be required in the continued development and approval of our product candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, if and when such arrangements will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect our research and development expenses to increase over the next several years as our development programs progress and as we seek to initiate clinical trials. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates.

 

Research and development expenses include the following:

 

  · employee-related expenses, such as salaries and share-based compensation;

 

  · expenses relating to outsourced and contracted services, such as CROs, external laboratories and consulting, research and advisory services;

 

  · preclinical study expenses and related developmental costs; and

 

  · costs associated with regulatory compliance.

 

We recognize research and development expenses as we incur them.

 

In the third quarter of 2020, we saw a shift away from research and development costs to general and administrative expenses as we executed our review of strategic alternatives focused on maximizing shareholder value. This has been undertaken while ensuring that we maintain the viability of our research and development assets and continue to maintain full and extensive protection our intellectual property.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of personnel costs, including share-based compensation related to directors and employees, facility costs, patent application and maintenance expenses, and external professional service costs, including legal, accounting, audit, finance, business development, investor relations and human resource services, and other consulting fees. Beginning with the third quarter of 2020, our general and administrative expenses also include initial costs related to the engagement of advisors in connection with our review of strategic alternatives to maximize shareholder value.

 

14

 

 

Finance (Income) Expense, Net

 

Finance (Income) expense, net, consisted primarily of finance expenses recorded due to revaluation of investor warrants at fair value during a period where these could not be classified within equity (for more details, see Note [7a] in “Item 1. Financial Statements Unaudited” above), offset by interest income received on the Company’s cash and cash equivalents and foreign currency exchange gains and losses.

 

Restructuring Expense

 

We have recognized restructuring provisions for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made to this end, we have recorded restructuring expenses comprised principally of contract termination costs, employee severance and associated termination costs related to the reduction of our workforce.

 

One-time termination benefits are expensed at the date the employees are notified, unless the employees must provide future services beyond a minimum retention period, in which case the benefits are expensed ratably over the future service periods. A provision for contract termination costs, in which a contract is terminated or the entity will continue to incur costs under a contract for its remaining term without economic benefit (an onerous contract), is recognized only when the contract is terminated or when the entity permanently ceases using the rights granted under the contract.

 

Pursuant to our strategic decision to temporarily reduction development of the pan-RAS-inhibitor program and to preserve liquid resources, we decided to undertake certain cost-saving measures. These measures included severing employees and contract terminations.. . With regards to the resignation of Dr. Frank Haluska the Company has a potential maximum exposure of up to $0.4 million relating to claims of “Good Reason” resignation. It is the our position that the CEO resigned without Good Reason, is not entitled to severance, and the Company will contest any and all claims for severance.

 

Results of Operations

 

Below is a summary of our results of operations for the periods indicated:

 

   September 30,   Increase/(decrease)   September 30,   Increase/(decrease) 
   2020   2019   $   %   2020   2019   $   % 
   (in thousands) 
Operating expenses:                                        
Research and development  $1,252   $5,565   $(4,313)   -78%  $3,609   $12,276   $(8,667)   -71%
General and administrative   1,125    1,705    (580)   -34%   5,126    4,958    168    3%
Restructuring expense   79    -    79    -    749    -    749    - 
Operating loss   (2,456)   (7,270)   (4,814)   66%   (9,484)   (17,234)   (7,750)   45%
Financing (income) expense, net   (7)   (102)   95    -93%   (19)   4,286    (4,305)   -100%
Net loss  $(2,449)  $(7,168)  $(4,719)   66%  $(9,465)  $(21,520)  $(12,055)   56%

 

Our results of operations have varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons of our operating results are not necessarily meaningful and should not be relied upon as indications of future performance.

 

15

 

 

Three and Nine Months Ended September 30, 2020 Compared to the Three and Nine Months Ended September 30, 2019

 

Research and development expenses

 

Research and development expense decreased by approximately $4.3 million, or 78%, and $8.7 million, or 71%, in the three and nine months ended September 30, 2020, respectively, from the comparable periods of 2019. The decrease is primarily due to the restructuring decisions made in July 2020and the related decision to temporarily reduction our research activities on the RAS programs and sever our research and development employees while continuing to undertake all necessary actions for the maintenance of the program, its assets and all related intellectual property and licenses. Research and development expenses include charges that amounted to $1.03 million for discontinuation of clinical development activities and $0.5 million for severance.

 

General and administrative expenses

 

General and administrative costs decreased by approximately $0.6 million, or 34%, and increased by approximately$0.2 million, or 3%, in the three and nine months ended September 30, 2020, respectively, from the comparable period of 2019. The decrease is primarily due the restructuring decisions made in July 2020 as we rationalized our general and administrative employees and other corporate activities.

 

Restructuring expense

 

In November 2019, we decided to discontinue our Phase 2 Codex study in patients with BCG-unresponsive NMIBC. In connection with this decision, we are required to make certain payments under contracts with CROs and with other manufactures of the drug in order to terminate the contracts and close the trials. Moreover, the restructuring plan included a reduction in the workforce of seven employees.

 

In January 2020, our Board of Directors approved management’s recommendation to close our office and laboratories located in Israel. The closure resulted in the termination of employment of the Company’s remaining five Israeli employees.

 

Restructuring expenses incurred during the second and third quarters of 2020 were comprised principally of contract termination costs, employee severance and associated termination costs related to the reduction of our workforce.

 

In July 2020, we made the strategic decision to temporarily reduction development of our RAS program and to institute various cost savings measures to preserve liquid resources. At the same time we continued to actively pursue the maintenance of our Licensing Agreement with ADT and protection of our intellectual property assets. The cost saving activities included severing employees and contract termination with outsourced contractors working on clinical activities.

  

Financing (income) expense, net

 

Financing (income) expense, net decreased by approximately $0.1 million, or 93%, and $4.3 million, or 100%, in the three and nine months ended September 30, 2020, respectively, from the comparable periods of 2019.

 

In the three and nine months ended September 30, 2020, finance expense was primarily interest income, foreign currency exchange rate gains and gains associated with the sale of laboratory equipment from our now closed Israeli operation.

 

16

 

 

For the three and nine months ended September 30, 2019, finance expense of was primarily related to the revaluation of investor warrants at fair value during a period where these could not be classified within shareholders’ equity, due to the following circumstances:

 

On initial measurement, the warrants together with their price protections were classified as equity instruments that are not subsequently measured at fair value, and thus we allocated the proceeds according to the relative fair value of the instruments. However, we changed our functional currency from NIS to USD as of January 1, 2019. Due to this change from this date, the exercise price of the warrants was no longer denominated in our functional currency and the warrants were therefore not considered indexed to our own stock according to ASC 815-40 and no longer met all the criteria to be classified within equity. Therefore, the warrants were reclassified as a liability at their fair value as of January 1, 2019, and any difference was accounted for as an adjustment to equity. Upon our Nasdaq initial public offering of February 14, 2019, the warrants’ exercise price currency was changed to US dollars. As a result, the warrants were reclassified within equity. Consequently, the warrants were measured at fair value from January 1, 2019 until February 14, 2019, with resulting finance expenses of $4.6 million, until they were reclassified within equity.

 

Cash Flows

 

The table below shows a summary of our cash flow activities for the periods indicated:

 

   Nine months ended         
   September 30,   Increase/(decrease) 
   2020   2019   $   % 
   (in thousands)         
Net cash used in operating activities  $(11,022)  $(10,544)  $478    5%
Net cash provided by (used in) investing activities   85    (346)   (431)   -125%
Net cash provided by financing activities   -    26,621    (26,621)   -100%
Net increase (decrease) in cash, cash equivalents and restricted cash  $(10,937)  $15,731   $(26,668)   -170%

 

Operating activities

 

Net cash used in operating activities increased by $0.5 million, or 5%, for the nine months ended September 30, 2020 compared to the same period of 2019. Net loss adjusted for non-cash activities was $9.4 million for the nine months ended September 30, 2020 compared to $15.7 million for the nine months ending September 30, 2019, resulting in favorable cash flow of $6.4 million. This was more than offset by unfavorable changes in working capital of approximately $6.6 million. The unfavorable changes in working capital was primarily driven by a significant prepayment for contract manufacturing in 2018 which reversed and generated favorable cash flow in 2019 with no similar impact in 2020, and a decrease in accounts payables and accruals in 2020 reflecting the overall reduction in research and development expense in addition to payment of severance and contractual cancellation costs associated with restructuring activities accrued at December 31, 2019.

 

Investing activities

 

Investing activities in the nine months ended September 30, 2020 reflect net proceeds of $0.1 million from the sale of laboratory equipment from our now closed facility in Israel, partially offset by purchases of fixed assets. Investing activities in the nine months ended September 30, 2019 were purchases of fixed assets.

 

Financing activities

 

Financing activities in the nine months ended September 30, 2019 reflect the net proceeds from our IPO on February 14, 2019. There were no financing activities in the nine months ended September 30, 2020.

 

17

 

 

Contractual Commitments

 

The Company’s contractual commitments are as follows at September 30, 2020 (in thousands):

  

    Operating Lease  
Remainder of 2020   $                      71  
2021     189  
2022     16  
Total   $ 276  

 

Effects of Currency Fluctuation

 

Currency fluctuations could affect us through increased or decreased costs, mainly for goods and services acquired outside of the United States. Currency fluctuations have not had a material effect on our results of operations during the nine months ended September 30, 2020 or 2019.

 

Off-Balance Sheet Arrangements

 

We have not entered into any transactions with unconsolidated entities as to which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that would expose us to material continuing risks, contingent liabilities or any other obligation under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

 

Critical Accounting Policies

 

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. GAAP. Comparative figures, which were previously presented and publicly reported in accordance with IFRS as issued by the International Accounting Standards Board, have been adjusted as necessary to be compliant with our policies under U.S. GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail throughout this section. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

For a discussion of our critical accounting policies, please read Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2019 Form 10-K. There have been no material changes to these critical accounting policies since our 2019 Form 10-K.

 

Recently-Issued Accounting Pronouncements

 

Certain recently-issued accounting pronouncements are discussed in Note [2], Summary of Significant Accounting Policies, to the unaudited condensed consolidated financial statements included in “Item 1. Financial Statements Unaudited.”

 

Liquidity and Capital Resources

 

The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company has incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit at September 30, 2020 of $114.9 million. The Company has financed operations to date primarily through public and private placements of equity securities. The Company anticipates that it will continue to incur net losses for the foreseeable future, including in connection with costs associated with its strategic review process. The Company believes that its existing cash and cash equivalents will only be sufficient to fund its projected cash needs into the first quarter of 2021. Accordingly, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. To meet future capital needs, the Company would need to raise additional capital through equity or debt financing or other strategic transactions. However, any such financing may not be on favorable terms or even available to the Company. The failure of the Company to obtain sufficient funds on commercially-acceptable terms when needed, would have a material adverse effect on the Company’s business, results of operations and financial condition. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of the Company’s expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company’s expenses could prove to be significantly higher than it currently anticipates.

 

18

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are an emerging growth company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are not required to provide the information under this item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Board of Directors (currently acting in the capacity of our principal executive officer) and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of September 30, 2020, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

19

 

  

 

PART II. – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.

 

Item 1A. Risk Factors

 

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 17, 2020, under the heading “Risk Factors” except as discussed below, and investors should review the risks provided in such Form 10-K and below, prior to making an investment in our company. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in the Form 10-K for the year ended December 31, 2019 under “Risk Factors” or below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price.

 

There can be no assurance that our review of strategic alternatives will result in any additional shareholder value, and speculation and uncertainty regarding the outcome of our review of strategic alternatives may adversely impact our business, financial condition and results of operations.

 

In July 2020, we engaged Oppenheimer & Co. to act as our financial advisor to conduct a review of strategic alternatives focused on maximizing shareholder value. There can be no assurances that the strategic alternatives review process will result in the announcement or consummation of any strategic transaction, or that any resulting plans or transactions will yield additional value for shareholders. Any potential transaction will be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction and the availability of financing. If we fail to successfully complete a strategic transaction, we may not be able to otherwise source adequate liquidity to fund our operations, meet our obligations, and continue as a going concern.

 

The process of exploring strategic alternatives could adversely impact our business, financial condition and results of operations. We expect to incur substantial expenses associated with identifying and evaluating potential strategic alternatives, and may incur substantial expenses associated with consummating a strategic alternative, if any is consummated, including those related to equity compensation, severance pay, legal, accounting and financial advisory fees, the payment of potential liabilities related to early termination of pre-existing contracts and other fees and payments that may be payable in the event of a strategic transaction.

 

In addition, the process may be time consuming and disruptive to our business operations, could divert the attention of management and the Board of Directors from our business, could require that we make changes to our headcount, may negatively impact our ability to attract, retain and motivate key employees, and could expose us to potential litigation in connection with this process or any resulting transaction. Further, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to our future could cause our stock price to fluctuate significantly.

 

20

 

 

Our ADSs are listed for trading on Nasdaq. On April 15, 2020, we received a deficiency letter from Nasdaq notifying us that, for the last 30 consecutive business days, the closing bid price of the ADSs has not been maintained at the minimum required closing bid price of at least $1.00 per ADS, as required for continued listing on the Nasdaq Capital Market. We were provided an initial period of 180 calendar days, or until October 12, 2020, to regain compliance. One June 5, 2020 we received a letter from Nasdaq notifying us that we had regained compliance with the exchange’s continued listing requirements.

 

Although we have regained compliance with the Nasdaq listing requirements, Nasdaq will continue to monitor our ongoing compliance. No assurance can be given that we will continue to meet applicable Nasdaq continued listing standards. Failure to meet applicable Nasdaq continued listing standards could result in a delisting of the ADSs, which could materially reduce the liquidity of our ADSs and result in a corresponding material reduction in the price of our ADSs. In addition, delisting could harm our ability to raise capital on terms acceptable to us, or at all, inhibit our ability to engage in a strategic transaction and lead to potential loss of confidence by investors and other stakeholders.

 

21

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

[None.]

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

[None.]

 

Item 6. Exhibits.

 

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.

 

                Incorporate
by
       
Exhibit
Number
  Description   Form   File No   Date of
Filing
  Exhibit
No.
 

Filed

Herewith

31.1   Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.                   X
                         
31.2   Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.                   X
                         
32.1(1)   Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                   X
                         
32.2(1)   Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                   X
                         
101.INS   XBRL Instance Document                   X
                         
101.SCH   Inline XBRL Taxonomy Extension Schema Document                   X
                         
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document                   X
                         
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document                   X
                         
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document                   X
                         
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document                   X

 

(1) The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

 

22

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 16, 2020

 

  ANCHIANO THERAPEUTICS LTD.
 
  By:     /s/ Neil Cohen
    Neil Cohen
(Principal Executive Officer)

 

23

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 16, 2020

 

  ANCHIANO THERAPEUTICS LTD.
     
  By:     /s/ Andrew Fine
    Andrew Fine
    Chief Financial Officer
    (Principal Accounting Officer and Principal Financial Officer and Duly Authorized Signatory)

 

24

EX-31.1 2 tm2029629d1_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

Certification of Periodic Report under Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Neil Cohen, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Anchiano Therapeutics Ltd.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 16, 2020

  /s/ Neil Cohen
  Neil Cohen
  (Principal Executive Officer)

 

 

 

EX-31.2 3 tm2029629d1_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

 

Certification of Periodic Report under Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Andrew Fine, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Anchiano Therapeutics Ltd.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 16, 2020

  /s/ Andrew Fine
  Andrew Fine

 

 

Chief Financial Officer

(Principal Accounting Officer and Principal Financial Officer)

  

 

 

EX-32.1 4 tm2029629d1_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

Certification Of
Principal Executive Officer
Pursuant To 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of The Sarbanes-Oxley Act Of 2002

 

In connection with the Quarterly Report of Anchiano Therapeutics Ltd. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Neil Cohen, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

 

  1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2) The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

 

 

Date: November 16, 2020 /s/ Neil Cohen
  Neil Cohen
  (Principal Executive Officer)

 

 

EX-32.2 5 tm2029629d1_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

 

Certification Of
Principal Financial Officer
Pursuant To 18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 Of The Sarbanes-Oxley Act Of 2002

 

In connection with the Quarterly Report of Anchiano Therapeutics, Ltd. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew Fine, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2) The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

  

Dated: November 16, 2020 /s/ Andrew Fine
  Andrew Fine
  Chief Financial Officer
  (Principal Financial Officer and Principal Accounting Officer)

 

 

EX-101.INS 6 ancn-20200930.xml XBRL INSTANCE DOCUMENT 0001534248 2019-02-14 0001534248 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0001534248 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-06-30 0001534248 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0001534248 us-gaap:RetainedEarningsMember 2020-09-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0001534248 us-gaap:RetainedEarningsMember 2020-06-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0001534248 2020-06-30 0001534248 us-gaap:RetainedEarningsMember 2019-12-31 0001534248 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001534248 us-gaap:RetainedEarningsMember 2019-09-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0001534248 us-gaap:RetainedEarningsMember 2019-06-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0001534248 2019-06-30 0001534248 us-gaap:RetainedEarningsMember 2018-12-31 0001534248 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001534248 us-gaap:CommonStockMember 2020-09-30 0001534248 us-gaap:CommonStockMember 2020-06-30 0001534248 us-gaap:CommonStockMember 2019-12-31 0001534248 us-gaap:CommonStockMember 2019-09-30 0001534248 us-gaap:CommonStockMember 2019-06-30 0001534248 us-gaap:CommonStockMember 2018-12-31 0001534248 srt:MinimumMember ancn:TwoThousandElevenShareOptionPlanMember 2020-09-30 0001534248 srt:MaximumMember ancn:TwoThousandElevenShareOptionPlanMember 2020-09-30 0001534248 srt:MinimumMember ancn:TwoThousandElevenShareOptionPlanMember 2019-09-30 0001534248 srt:MaximumMember ancn:TwoThousandElevenShareOptionPlanMember 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember ancn:TwoThousandElevenShareOptionPlanMember 2019-01-01 2019-12-31 0001534248 us-gaap:EmployeeStockOptionMember ancn:TwoThousandElevenShareOptionPlanMember 2019-12-31 0001534248 srt:MinimumMember ancn:TwoThousandElevenShareOptionPlanMember 2020-01-01 2020-09-30 0001534248 srt:MaximumMember ancn:TwoThousandElevenShareOptionPlanMember 2020-01-01 2020-09-30 0001534248 srt:MinimumMember ancn:TwoThousandElevenShareOptionPlanMember 2019-01-01 2019-09-30 0001534248 srt:MaximumMember ancn:TwoThousandElevenShareOptionPlanMember 2019-01-01 2019-09-30 0001534248 ancn:TwoThousandElevenShareOptionPlanMember 2020-01-01 2020-09-30 0001534248 ancn:TwoThousandElevenShareOptionPlanMember 2019-01-01 2019-09-30 0001534248 us-gaap:EmployeeSeveranceMember 2020-07-01 2020-09-30 0001534248 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0001534248 2018-01-31 0001534248 2018-05-01 2018-05-31 0001534248 2020-02-01 0001534248 2019-01-01 2019-02-14 0001534248 us-gaap:MeasurementInputSharePriceMember 2019-02-14 0001534248 us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-02-14 0001534248 us-gaap:MeasurementInputOptionVolatilityMember 2019-02-14 0001534248 us-gaap:MeasurementInputSharePriceMember 2019-01-01 0001534248 us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-01-01 0001534248 us-gaap:MeasurementInputOptionVolatilityMember 2019-01-01 0001534248 us-gaap:IPOMember 2019-02-14 0001534248 us-gaap:PrivatePlacementMember 2018-06-30 0001534248 2018-12-31 0001534248 ancn:DiscontinuationOfExternalClinicalDevelopmentMember 2020-10-20 2020-10-20 0001534248 ancn:DiscontinuationOfExternalClinicalDevelopmentMember 2020-07-01 2020-09-30 0001534248 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001534248 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001534248 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2020-07-01 2020-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2020-07-01 2020-09-30 0001534248 us-gaap:EmployeeStockOptionMember ancn:TwoThousandElevenShareOptionPlanMember 2020-07-01 2020-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2020-01-01 2020-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2020-01-01 2020-09-30 0001534248 us-gaap:EmployeeStockOptionMember ancn:TwoThousandElevenShareOptionPlanMember 2020-01-01 2020-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2019-07-01 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2019-07-01 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember ancn:TwoThousandElevenShareOptionPlanMember 2019-07-01 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2019-01-01 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember ancn:TwoThousandElevenShareOptionPlanMember 2019-01-01 2019-09-30 0001534248 us-gaap:EmployeeStockOptionMember ancn:TwoThousandElevenShareOptionPlanMember 2019-01-01 2019-09-30 0001534248 2020-11-16 0001534248 us-gaap:PrivatePlacementMember 2018-01-01 2018-12-31 0001534248 us-gaap:PrivatePlacementMember 2020-01-01 2020-09-30 0001534248 ancn:CroAndManufacturingOtherMember 2020-09-30 0001534248 us-gaap:EmployeeSeveranceMember 2019-12-31 0001534248 ancn:CroAndManufacturingOtherMember 2019-12-31 0001534248 us-gaap:FacilityClosingMember 2020-01-01 2020-09-30 0001534248 ancn:CroAndManufacturingOtherMember 2020-01-01 2020-09-30 0001534248 2020-09-30 0001534248 2019-12-31 0001534248 us-gaap:EmployeeStockOptionMember ancn:TwoThousandElevenShareOptionPlanMember 2020-09-30 0001534248 us-gaap:IPOMember 2019-02-14 2019-02-14 0001534248 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001534248 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001534248 2020-01-01 2020-06-30 0001534248 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001534248 2020-07-01 2020-09-30 0001534248 2019-07-01 2019-09-30 0001534248 2019-09-01 2019-09-30 0001534248 2019-09-30 0001534248 us-gaap:PrivatePlacementMember 2018-06-01 2018-06-30 0001534248 2018-05-31 2018-05-31 0001534248 2018-01-01 2018-01-31 0001534248 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001534248 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001534248 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001534248 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0001534248 2019-01-01 2019-06-30 0001534248 2019-01-01 2019-09-30 0001534248 2020-01-01 2020-09-30 utr:sqft iso4217:ILS xbrli:shares iso4217:USD xbrli:shares ancn:plan xbrli:shares xbrli:pure iso4217:USD <div> <div> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Accrued and other current liabilities consist of the following for the periods indicated (in thousands):</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Accrued expenses</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,361</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 372</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Restructuring accrual</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 238</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,161</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payroll and related</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 60</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Liability for employee rights upon retirement</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 262</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 1,620</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 2,855</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">3.&nbsp;Accrued expenses and other</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Accrued and other current liabilities consist of the following for the periods indicated (in thousands):</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Accrued expenses</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,361</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 372</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Restructuring accrual</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 238</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,161</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payroll and related</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 60</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Liability for employee rights upon retirement</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 262</font></p> </td> </tr> <tr> <td valign="bottom" style="width:73.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 1,620</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 2,855</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 4652000 0 8198000 0 8198000 0 0 0 -3628000 0 -3628000 0 0 0 400000 200000 100000 0.80 3000000 P90D -4286000 102000 19000 7000 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;color:#000000;">5. </font><font style="display:inline;">License Agreement</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In September&nbsp;2019, the Company announced that it entered into an option to license agreement with ADT Pharmaceuticals, LLC (&#x201C;ADT&#x201D;). Pursuant to the terms and conditions set forth in the agreement, the parties agreed to conduct research and development activities of novel small-molecule inhibitors (RAS and PDE10/&#x3B2;-catenin). As part of the arrangement, the Company is primarily responsible for the research, development, manufacturing and regulatory activities and ADT assists with the research activities as necessary in exchange for a quarterly fee from the Company. In connection with the agreement, ADT also granted the Company exclusive rights to research, develop, manufacture and commercialize the aforementioned compounds relating to patents owned by ADT and any products containing such compounds worldwide. In consideration for the rights granted under the agreement, the Company committed to pay ADT (i)&nbsp;a $3 million upfront fee; (ii)&nbsp;a fee upon transfer of the know-how and intellectual property rights to the Company; and then (iii)&nbsp;additional payments, including milestone and royalty payments. The Company has the ability to terminate the agreement at any time in its entirety or on a compound-by-compound basis after providing 90&nbsp;days written notice to ADT. The upfront fee was paid in the third quarter of 2019. The Company accounted for the upfront fee and additional payments as a research and development expenses and continues to make ongoing payments to ADT in support of its maintenance of the Company's assets.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In April 2020, the Company notified Yissum Technology Transfer Company of the Hebrew University Ltd. (&#x201C;Yissum&#x201D;) that as a result of the Company&#x2019;s previous decision to discontinue clinical development of inodiftagene, it will cease payments to maintain intellectual property (&#x201C;IP&#x201D;) it licensed from Yissum that supported the development and as related to a licensing and development agreement between the parties (&#x201C;License Agreement&#x201D;). In August 2020 the Company agreed with Yissum on termination of&nbsp;&nbsp;the License Agreement, the Company destroyed or returned all IP documentation to Yissum and Yissum and the Company mutually waived, released and discharged the other from all claims of any type.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> -14374000 -14374000 -7168000 -7168000 -7016000 -7016000 -2449000 -2449000 1652560 1241466 5 5 2 8198000 0 3628000 0 2161000 238000 749000 502000 247000 2908000 2572000 336000 238000 238000 -114900000 3.842 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Derivative&nbsp;Financial&nbsp;Instrument</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:17.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">February 14, 2019</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January 1, 2019</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share price</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.84</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.50</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected term</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">End of 2022</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">End of 2022</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk free rate</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.49</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.37</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Volatility</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 52</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 48</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 0 2652174 0.4286 P5Y 2713159 0 85000 false --12-31 Q3 2020 2020-09-30 10-Q 0001534248 37099352 Yes true false Non-accelerated Filer Yes Anchiano Therapeutics Ltd. false true American Depositary Shares, each representing five ordinary shares, no par value per share ANCN 2855000 1620000 875000 482000 372000 1361000 872000 872000 119468000 119375000 1070000 632000 438000 322000 168000 154000 -96000 70000 -166000 -357000 -67000 -290000 3985858 10975959 3129343 10975959 19755000 7689000 18211000 7388000 1030000 1030000 23241000 17575000 6768000 6768000 7640000 23371000 23371000 17705000 6768000 6768000 15731000 -10937000 16.20 4.32 6207330 0 0 0 0 0 0 0 0 0 100000000 500000000 37099352 37099352 37099352 37099352 0 0 70000 77000 48 1.37 2.50 52 2.49 1.84 -0.64 -0.19 -0.26 -0.07 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;">9</font><font style="display:inline;">. Net Loss per share</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Basic loss per share is computed on the basis of the net loss for the period divided by the weighted-average number of ordinary shares outstanding during the period. Diluted loss per share is based upon the weighted-average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options which are included under the treasury stock method when dilutive.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The following ordinary shares underlying stock options and warrants were excluded from the calculation of diluted net loss per ordinary share, because their effect would have been anti-dilutive for the three and nine&nbsp;month periods presented:</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:31.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September 30</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Stock Options</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,129,343</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,985,858</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Warrants</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,975,959</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,975,959</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 60000 21000 4570000 0 19000 4958000 1705000 5126000 1125000 605000 0 913000 -393000 -621000 -1235000 -70000 -5000 -4823000 -16000 4000 0 2400 false P5Y <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">4. Leases</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In January&nbsp;2018, the Company signed an agreement to rent a laboratory and offices in Jerusalem through May&nbsp;2023. The Company had an option to extend the agreement by another five&nbsp;years. The annual rent (including management fees) is approximately $0.4 million and is linked to the Israeli Consumer Price Index. Pursuant to the agreement, bank guarantees of $0.1 million were provided to the property owner. In January&nbsp;2020, pursuant to the Company&#x2019;s decision to close its Israeli operations, the agreement was modified such that the Company vacated the facilities on May&nbsp;30, 2020 but will continue to make scheduled lease payments through October&nbsp;31, 2020. The Company recorded restructuring expense of $247,000 related to the modification of the Israeli lease agreement and settled all obligations associated with the lease.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In May&nbsp;2018, the Company signed an agreement to rent space for its headquarter offices in Cambridge, Massachusetts. This agreement was amended in October&nbsp;2019 to reflect relocating to a new 2,400 square foot suite within the same facility effective February&nbsp;1, 2020. The annual rent is approximately $0.2 million. The amended lease term ends January&nbsp;31, 2022 and there are no options to extend the lease. </font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The Company currently maintains the lease in good standing and is assessing the ability of the staff to continue working remotely under the restrictions of COVID-19. .</font> </p><div /></div> </div> 4846000 2338000 19755000 7689000 4121000 2275000 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">1. The Company and Basis of Presentation</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Anchiano Therapeutics&nbsp;Ltd. is an early-stage preclinical biopharmaceutical company committed to discovering and developing new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies. The Company is developing small-molecule pan-mutant RAS inhibitors and inhibitors of PDE10 and the &#x3B2;-catenin pathway.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In November&nbsp;2019, the Company discontinued clinical development of inodiftagene vixteplasmid. After a thorough evaluation of the available data, the Company determined there was a low probability of surpassing the pre-defined futility threshold at the planned interim analysis of its Phase 2 Codex study, which was evaluating inodiftagene vixteplasmid in patients with BCG-unresponsive non-muscle-invasive bladder cancer (&#x201C;NMIBC&#x201D;), and announced the discontinuation of the study.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In January 2020, the Board of Directors of the Company approved management&#x2019;s recommendation to close the Company&#x2019;s office and laboratories located in Israel. Following the closure of the Israeli facilities at the end of May 2020, the Company&#x2019;s sole remaining office is located in Cambridge, Massachusetts (for details, see Note 4 below).&nbsp;&nbsp;The Company currently maintains the lease on this facility in good standing and is also assessing the ability of the staff to continue working remotely under the restrictions of COVID-19.&nbsp;&nbsp; </font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In March 2020 the World Health Organization declared the global novel coronavirus (COVID-19) outbreak a pandemic. As of October 14, 2020, the Company&#x2019;s operations have not been significantly impacted by the COVID-19 outbreak. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned pre-clinical development activities.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">On July 2, 2020, the Company&#x2019;s Chief Executive Officer Dr. Frank Haluska sent a letter to the Company&#x2019;s Chairman outlining Dr. Haluska&#x2019;s belief that events had occurred that were sufficient to trigger his ability to resign for &#x201C;Good Reason&#x201D; under his employment agreement. The Board informed Dr. Haluska that it disagreed with the letter&#x2019;s assertions regarding &#x201C;Good Reason&#x201D; and treated the letter as a constructive resignation effective as of July 2, 2020. On July 12, 2020, Dr. Frank Haluska tendered his written resignation from the Company&#x2019;s Board of Directors, effective immediately. Dr. Haluska referenced the matters articulated in his letter of July 2, 2020, and the Company&#x2019;s response and actions following receipt of the letter as the basis for his resignation from the Board. It is the Company&#x2019;s position, based on its legal counsel, that the CEO resigned without Good Reason, is not entitled to severance, and the Company will contest any and all claims for severance. Prior to the appointment of Mr. Neil Cohen as CEO in October 2020 (see below) the Board handled all matters related to CEO duties.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">On October 20, 2020, the Company appointed Mr. Neil Cohen as Chief Executive Officer of the Company, effective immediately.&nbsp;&nbsp;Mr. Cohen will continue to serve as a member of the Company&#x2019;s board of directors. The Company also appointed Andrew Fine to serve as the Chief Financial Officer of the Company, effective immediately. Mr. Fine previously served as the Company&#x2019;s Interim Chief Financial Officer pursuant to a subcontracting agreement.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In light of business circumstances, and in order to conserve cash and preserve optionality while alternatives are being identified and assessed, the Company made a decision during July 2020 to undertake reductions in headcount and other cost saving measures. These include plans to temporarily reduce its internal and external research and development work on the Company's pan-RAS-inhibitor program until there is greater clarity regarding Anchiano's ability to fund the program.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The Company continues to undertake actions for the promotion of the program and its assets and towards strengthening the protection of all related intellectual property.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">As a result of the above the Company took&nbsp;&nbsp;charges associated with severance and, discontinuation of external clinical development activities,. These charges amounted to $1.03 million for discontinuation of external clinical development activities and $0.5 million for severance (see Notes 6 and 7 below).</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The Company is incorporated and registered in Israel. The Company&#x2019;s American Depositary Shares ("ADSs"), each representing five ordinary shares of the Company with no par value (the "ordinary shares"), began trading on the Nasdaq Capital Market (&#x201C;Nasdaq&#x201D;) in February&nbsp;2019 under the symbol "ANCN". The Company&#x2019;s ordinary shares traded on the Tel Aviv Stock Exchange (&#x201C;TASE&#x201D;) between August&nbsp;2006 and June&nbsp;2019, at which time the Company voluntarily delisted from the TASE. The Company wholly owns a subsidiary, Anchiano Therapeutics Israel&nbsp;Ltd., which itself wholly owns a Delaware-incorporated subsidiary, Anchiano Therapeutics,&nbsp;Inc.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size: 10pt;"> <font style="display:inline;">Liquidity</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company has incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit at September 30, 2020 of $114.9 million. The Company has financed operations to date primarily through public and private placements of equity securities. The Company anticipates that it will continue to incur net losses for the foreseeable future. The Company believes that its existing cash and cash equivalents will only be sufficient to fund its projected cash needs into the first quarter of 2021. Accordingly, these factors, among others, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&nbsp;To meet future capital needs, the Company would need to raise additional capital through equity or debt financing or other strategic transactions.&nbsp;However, any such financing may not be on favorable terms or may not be available to the Company on any terms.&nbsp;The failure of the Company to obtain sufficient funds on commercially-acceptable terms when needed, would have a material adverse effect on the Company&#x2019;s business, results of operations and financial condition. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of the Company&#x2019;s expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company&#x2019;s expenses could prove to be significantly higher than it currently anticipates. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size: 10pt;"> <font style="display:inline;">Unaudited Interim Financial Information</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The interim condensed consolidated financial statements included in this quarterly report are unaudited. The unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;) and applicable rules&nbsp;and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company&#x2019;s financial position as of September 30, 2020, and its results of operations for the three and nine&nbsp;months ended September 30, 2020 and 2019, changes in shareholders&#x2019; equity for the three and nine&nbsp;months ended September 30, 2020 and 2019, and cash flows for the nine&nbsp;months ended September 30, 2020 and 2019. The results of operations for the three and nine&nbsp;months ended September 30, 2020 are not necessarily indicative of the results to be expected for the&nbsp;year ending December&nbsp;31, 2020 or for any other future annual or interim period. The December&nbsp;31, 2019 balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. These financial statements should be read in conjunction with the audited financial statements included in the Company&#x2019;s Form&nbsp;10&#8209;K for the&nbsp;year ended December&nbsp;31, 2019 as filed with the SEC. The Company&#x2019;s significant accounting policies are disclosed in the audited financial statements for the&nbsp;year ended December&nbsp;31, 2019 included in the Company&#x2019;s Form&nbsp;10&#8209;K. Since the date of such financial statements, there have been no changes to the Company&#x2019;s significant accounting policies.</font> </p><div /></div> </div> 26621000 0 -346000 85000 -10544000 -11022000 -21520000 -7168000 -9465000 -2449000 17234000 7270000 9484000 2456000 391000 173000 725000 63000 1199000 234000 187000 52000 2855000 1620000 3879000 0 346000 34000 262000 636000 620000 <div> <div> <p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">b.</font><font style="display:inline;font-style:italic;"> &nbsp;&nbsp;&nbsp;Reclassifications</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Certain prior&nbsp;year amounts shown in the accompanying unaudited condensed consolidated financial statements have been reclassified to conform to the 2020 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total shareholders&#x2019; equity, net loss, or loss per share.</font> </p><div /></div> </div> 30500000 30500000 0 22900000 0 119000 -21520000 -9465000 158000 15000 12276000 5565000 3609000 1252000 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">7. Research and development</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">As noted above, and in conjunction with the Company&#x2019;s decision to reassess its strategy around research and development efforts of its scientific and assets,&nbsp;&nbsp;in the third quarter the Company took&nbsp;&nbsp;charges associated with severance and, discontinuation of clinical development activities,. These charges amounted to $1.03 million for discontinuation of clinical development activities and $0.5 million for severance of research and development personnel.</font> </p><div /></div> </div> 130000 0 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">6. Restructuring</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication has been made to those affected.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The Company has recorded restructuring expenses related principally to contract termination costs due to the discontinuation of the clinical trials to CROs and manufacturers and contractual involuntary termination benefits to employees which have been accounted for as ongoing benefit arrangements and associated termination costs related to the reduction of its workforce.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">One-time termination benefits are expensed at the date the employees are notified, unless the employees must provide future services beyond a minimum retention period, in which case the benefits are expensed ratably over the future service periods. A provision for contract termination costs, in which a contract is terminated or the entity will continue to incur costs pursuant to contract for its remaining term without economic benefit, is recognized only when the contract is terminated or when the entity permanently ceases using the rights granted under the contract.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In November&nbsp;2019, the Company decided to discontinue its Phase 2 Codex study in patients with BCG-unresponsive NMIBC. In connection with this decision, the Company is required to make certain payments under contracts with CROs and with manufactures of the drug in order to terminate the contracts and close the trials. This restructuring plan included a reduction in the workforce of seven employees.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In January&nbsp;2020, the Board of Directors approved management&#x2019;s recommendation to close the Company&#x2019;s office and laboratories located in Israel. In connection with this restructuring, the employment of the remaining five Israeli employees was terminated in the second quarter of 2020.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">As noted above, in conjunction with this decision the Company renegotiated its lease for Israeli laboratory and office space. In connection with this decision, the Company vacated the facilities on May&nbsp;31, 2020 but will continue to make scheduled lease payments through October&nbsp;31, 2020. In the first quarter of 2020, the Company recorded a restructuring charge to adjust its operating lease right of use asset and operating lease liability to reflect the loss on the early termination of the Israeli lease obligation.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The following table represents a roll forward of the restructuring and other activities noted above (in thousands):</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CRO,</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Facility&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;Manufacturing</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Severance-</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">and&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;and&nbsp;other&nbsp;related</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">related</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Leases</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance, January 1, 2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,572</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 336</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,908</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expenses</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;502</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 247</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;749</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Paid or consummed</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,835)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (336)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (247)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (3,138)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance, September&nbsp;30,&nbsp;2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 238</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 238</font></p> </td> </tr> </table></div> <p style="margin:0pt 0pt 0pt 40.3pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 247000 749000 79000 -105431000 -114896000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:31.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September 30</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Stock Options</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,129,343</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,985,858</font></p> </td> </tr> <tr> <td valign="bottom" style="width:68.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Warrants</font></p> </td> <td valign="bottom" style="width:00.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,975,959</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,975,959</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.30%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Three months ended </font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Nine months ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Research and development</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (290)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 154</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (166)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 438</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">General and administrative</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (67)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 168</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 70</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 632</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (357)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 322</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (96)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 1,070</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CRO,</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Facility&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;Manufacturing</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Severance-</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">and&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;and&nbsp;other&nbsp;related</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">related</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Leases</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance, January 1, 2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,572</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 336</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,908</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expenses</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;502</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 247</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;749</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Paid or consummed</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,835)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (336)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (247)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (3,138)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance, September&nbsp;30,&nbsp;2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 238</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 238</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The fair value of each option granted in the nine&nbsp;months ended September 30, 2019 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Nine months ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Value of ordinary share</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$1.03 - $1.54</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected volatility</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">51.5% - 68.6%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2.2% - 2.5%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected term (years)</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">5.5 - 6.9</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The fair value of each option granted in the nine months ended September 30, 2020 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Nine months ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2020</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Value of ordinary share</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$0.15 - $0.17</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected volatility</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">64.9% - 67.4%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.30% to 0.39%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected term (years)</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">5.5 - 6.5</font></p> </td> </tr> </table></div> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value on January 1, 2019</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,628</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments-finance expenses</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,570</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value on February 14, 2019</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,198</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted&nbsp;Average&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Average&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Contractual&nbsp;Life&nbsp;in&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise&nbsp;Price</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Years</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Options outstanding - January 1, 2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,822,374</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.50</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8.5</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Granted</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 885,000</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Forfeited/expired/cancelled</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1,578,031)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Options outstanding - September&nbsp;30,&nbsp;2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,129,343</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.44</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7.9</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Options exercisable - September&nbsp;30,&nbsp;2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,389,840</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3.01</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7.5</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> -3138000 -2835000 -336000 -247000 500000 500000 1069000 -93000 0.00 0.00 P6Y10M24D P5Y6M P6Y6M P5Y6M 0.686 0.674 0.515 0.649 0.025 0.0039 0.022 0.0030 2389840 3.01 P7Y6M 1578031 885000 3822374 3129343 2.50 2.44 P8Y6M P7Y10M24D <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;">8</font><font style="display:inline;">. Shareholders&#x2019; Equity</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"> <font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;color:#000000;font-size:10pt;;"> a.</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">2018 Private Placement</font></p></td></tr></table></div> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In June&nbsp;2018, the Company completed a $22.9 million fundraising round from investors in the United States and Israel. In consideration for the investment, the Company issued 5,960,787 ordinary shares at a price per share of approximately $3.842, as well as 2,713,159 warrants to acquire additional shares equal to 80% of the shares issued, at an exercise price per share of NIS 16.20 (approximately $4.32). The warrants are exercisable for five&nbsp;years from December&nbsp;31, 2018, the closing date of the transaction, and may be exercised on a cashless basis.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">In addition, the investors were granted price protection rights (to shares and warrants) in the event of a future share issuance by the Company wherein the price does not increase by at least approximately 42.86% over the price per share in the fundraising (or is less than the adjusted price per share, if the price has already been adjusted). For details of an allocation that took place in 2019 pursuant to these rights, see Note&nbsp;7b below.&nbsp;The warrants and shares were recorded within equity on the issuance date.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Effective January&nbsp;1, 2019, the Company changed its functional currency from NIS to USD. Due to this change, the exercise price of the warrants was no longer denominated in the Company&#x2019;s functional currency and therefore not considered indexed to the Company&#x2019;s own shares according to ASC 815&#8209;40. Accordingly, the Company recorded the fair value of the warrants as a liability at January&nbsp;1, 2019.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Subsequently, upon the Company&#x2019;s Nasdaq initial public offering on February&nbsp;14, 2019, the warrants&#x2019; term was modified such that the exercise price currency was changed to USD. As a result, the warrants were once again considered indexed to the Company&#x2019;s own shares according to ASC 815&#8209;40. Accordingly, the fair value of the warrants at February&nbsp;14, 2019 was reclassified from a liability to equity on that date.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The following table summarizes the activity for the warrants whose fair value measurements are estimated utilizing Level 3 inputs:</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value on January 1, 2019</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,628</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments-finance expenses</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,570</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value on February 14, 2019</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,198</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The Company has determined the fair value of the warrants (a Level 3 valuation) as of January&nbsp;1, 2019 and February&nbsp;14, 2019. The fair value of these warrants was estimated by implementing the Probability-Weighted Expected Return Method or the Black-Scholes Method. The following parameters were used:</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Derivative&nbsp;Financial&nbsp;Instrument</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:17.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">February 14, 2019</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January 1, 2019</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share price</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.84</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.50</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected term</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">End of 2022</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">End of 2022</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk free rate</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.49</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.37</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Volatility</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 52</font></p> </td> <td valign="bottom" style="width:03.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 48</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;margin:0pt 0pt 12pt;"> <font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;;"> b.</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;margin:0pt 0pt 12pt;"> <font style="display:inline;color:#000000;">Public Offering</font></p></td></tr></table></div> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">On February&nbsp;14, 2019, the Company raised gross proceeds of $30.5 million in its Nasdaq initial public offering (&#x201C;IPO&#x201D;), allocating 2,652,174 ADSs, each representing five ordinary shares of the Company. The ADSs are listed under the symbol &#x201C;ANCN.&#x201D; In accordance with price protection rights granted in 2018 and activated in the offering (see Note&nbsp;7a above for details and accounting treatment), the Company issued an additional 8,262,800 ordinary shares (equivalent to 1,652,560 ADSs) to rights holders and adjusted their warrants to be exercisable for an additional 6,207,330 ordinary shares (equivalent to 1,241,466 ADSs).</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;"> <p style="font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;margin:0pt 0pt 12pt;"> <font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10pt;;"> c.</font> </p> </td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;margin:0pt 0pt 12pt;"> <font style="display:inline;color:#000000;">Share-based compensation</font></p></td></tr></table></div> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The Company has two share-based compensation plans under which share options or other share-based awards have been granted: the 2011 Share Option Plan and the 2017 Share Option Plan (the &#x201C;2017 Plan&#x201D;). The 2017 Plan replaced the 2011 Share Option Plan with respect to future grants; and, therefore, no further awards may be made under 2011 Share Option Plan. The Compensation Committee of the Board of Directors and the Board of Directors administer these plans.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The fair value of each option granted is estimated using the Black-Scholes option pricing method. The volatility is based on the Company&#x2019;s historical volatility. The risk-free interest rate assumption is based on observed Treasury yields over the expected term of the options granted with USD-denominated exercise prices (options granted in the past with NIS-denominated exercise prices used the equivalent Israeli government bond yields). The Company&#x2019;s management uses the mid-point between the vesting date and the contractual term for each vesting tranche or its expectations, as applicable, of each option as its expected term. The expected term of the options granted represents the period of time that granted options are expected to remain outstanding</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The fair value of each option granted in the nine&nbsp;months ended September 30, 2019 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Nine months ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Value of ordinary share</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$1.03 - $1.54</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected volatility</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">51.5% - 68.6%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2.2% - 2.5%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected term (years)</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">5.5 - 6.9</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The fair value of each option granted in the nine months ended September 30, 2020 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Nine months ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2020</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Value of ordinary share</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$0.15 - $0.17</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Dividend yield</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected volatility</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">64.9% - 67.4%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.30% to 0.39%</font></p> </td> </tr> <tr> <td valign="bottom" style="width:78.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected term (years)</font></p> </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:19.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">5.5 - 6.5</font></p> </td> </tr> </table></div> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The following table summarizes the number of options outstanding and exercisable as of September&nbsp;30, 2020:</font> </p> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted&nbsp;Average&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Average&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Contractual&nbsp;Life&nbsp;in&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise&nbsp;Price</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Years</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Options outstanding - January 1, 2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,822,374</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.50</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8.5</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Granted</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 885,000</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Forfeited/expired/cancelled</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1,578,031)</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Options outstanding - September&nbsp;30,&nbsp;2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,129,343</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.44</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7.9</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Options exercisable - September&nbsp;30,&nbsp;2020</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,389,840</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3.01</font></p> </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7.5</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The aggregate intrinsic value of both outstanding and exercisable options at September 30, 2020 is $0.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The following table illustrates the effect of share-based compensation on the statements of operations (in thousands):</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.30%;"> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Three months ended </font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Nine months ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Research and development</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (290)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 154</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (166)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 438</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">General and administrative</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (67)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 168</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 70</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 632</font></p> </td> </tr> <tr> <td valign="bottom" style="width:58.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (357)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 322</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (96)</font></p> </td> <td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 1,070</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The negative amounts for both Research and development and General and administrative reflect the forfeiture of vested stock options and the reversal of accrued compensation on account of future vesting on stock options that were granted to employees who were terminated as part of the Company's restructuring activities as mentioned above.</font> </p><div /></div> </div> 1.54 1.03 0.17 0.15 15575682 37099352 37099352 37099352 37099352 37099352 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">2.&nbsp;Summary of Significant Accounting Policies</font> </p> <p style="margin:0pt 0pt 12pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">a.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;color:#000000;"> &nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Use </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;color:#000000;">of Estimates</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis, including those related to share-based compensation, leases and derivatives. The Company&#x2019;s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">b.</font><font style="display:inline;font-style:italic;"> &nbsp;&nbsp;&nbsp;Reclassifications</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">Certain prior&nbsp;year amounts shown in the accompanying unaudited condensed consolidated financial statements have been reclassified to conform to the 2020 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total shareholders&#x2019; equity, net loss, or loss per share.</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 9805000 872000 87240000 0 -78307000 27249000 872000 119058000 0 -92681000 20402000 872000 119379000 0 -99849000 14909000 14909000 872000 119468000 0 -105431000 8157000 872000 119732000 0 -112447000 5351000 5351000 872000 119375000 0 -114896000 5960787 21523670 8262800 26500000 0 26500000 0 0 748000 0 748000 0 0 0 321000 0 321000 0 0 0 264000 0 264000 0 0 0 -357000 0 -357000 0 0 0 <div> <div> <p style="margin:0pt 0pt 12pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">a.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;color:#000000;"> &nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Use </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;color:#000000;">of Estimates</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis, including those related to share-based compensation, leases and derivatives. The Company&#x2019;s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.</font> </p><div /></div> </div> 3628000 8198000 33551494 37099352 37099352 37099352 EX-101.SCH 7 ancn-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Accrued expenses and other (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - The Company and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Research and development (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Shareholders' Equity - 2019 Public offering and 2018 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Shareholders' Equity - Warrants activity (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Shareholders' Equity - Fair Value assumptions of warrants and 2018 Reverse Split (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Shareholders' Equity - Fair value of stock options (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Shareholders' Equity - Summary of outstanding and exercisable options (Details) link:presentationLink link:calculationLink link:definitionLink 40806 - Disclosure - Shareholders' Equity - Share-based compensation expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Net Loss per share - Severance pay and Antidilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - The Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Accrued expenses and other link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Research and development link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Net Loss per share link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Accrued expenses and other (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Net Loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ancn-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ancn-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ancn-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 ancn-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2020
Nov. 16, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Period End Date Sep. 30, 2020  
Entity Registrant Name Anchiano Therapeutics Ltd.  
Trading Symbol ANCN  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Ex Transition Period false  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   37,099,352
Entity Central Index Key 0001534248  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Title of 12(b) Security American Depositary Shares, each representing five ordinary shares, no par value per share  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 6,768 $ 17,575
Prepaid expenses and other 620 636
Total current assets 7,388 18,211
Property and equipment, net 15 158
Operating lease right-of-use 234 1,199
Other non-current assets 52 187
Total assets 7,689 19,755
Current liabilities:    
Trade payables 482 875
Accrued expenses and other 1,620 2,855
Operating lease liability 173 391
Total current liabilities 2,275 4,121
Non-current operating lease liability 63 725
Total liabilities 2,338 4,846
Commitments and contingencies 0 0
Shareholders' equity:    
Ordinary shares, no par value - authorized 500,000,000 shares as of September 30, 2020 and 100,000,000 shares as of December 31,2019; issued and outstanding 37,099,352 shares at September 30, 2020 and December 31,2019 0 0
Paid-in capital 119,375 119,468
Currency translation differences reserve 872 872
Accumulated deficit (114,896) (105,431)
Total shareholders' equity 5,351 14,909
Total liabilities and shareholders' equity $ 7,689 $ 19,755
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2020
Dec. 31, 2019
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)    
Common Stock, Par or Stated Value Per Share $ 0 $ 0
Common Stock, Shares Authorized 500,000,000 100,000,000
Common Stock, Shares, Issued 37,099,352 37,099,352
Common Stock, Shares, Outstanding 37,099,352 37,099,352
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating expenses:        
Research and development $ 1,252 $ 5,565 $ 3,609 $ 12,276
General and administrative 1,125 1,705 5,126 4,958
Restructuring expense 79   749  
Total operating expenses 2,456 7,270 9,484 17,234
Finance (income) expense, net (7) (102) (19) 4,286
Net loss and comprehensive loss $ (2,449) $ (7,168) $ (9,465) $ (21,520)
Basic and diluted loss per share $ (0.07) $ (0.19) $ (0.26) $ (0.64)
Weighted average number of shares outstanding - basic and diluted 37,099,352 37,099,352 37,099,352 33,551,494
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
Ordinary shares
Paid-in capital
Currency translation differences reserve
Accumulated deficit
Total
Beginning balance at Dec. 31, 2018 $ 0 $ 87,240,000 $ 872,000 $ (78,307,000) $ 9,805,000
Beginning balance (in shares) at Dec. 31, 2018 15,575,682        
CHANGES DURING THE YEAR:          
Issuance of shares, net $ 0 26,500,000 0 0 26,500,000
Issuance of shares, net (in shares) 21,523,670        
Reclassification of warrants due to reassessment $ 0 (3,628,000) 0 0 (3,628,000)
Reclassification of warrants due to modification 0 8,198,000 0 0 8,198,000
Share-based compensation 0 748,000 0 0 748,000
Net loss       (14,374,000) (14,374,000)
Ending balance at Jun. 30, 2019 $ 0 119,058,000 872,000 (92,681,000) 27,249,000
Ending balance (in shares) at Jun. 30, 2019 37,099,352        
CHANGES DURING THE YEAR:          
Share-based compensation $ 0 321,000 0 0 321,000
Net loss       (7,168,000) (7,168,000)
Ending balance at Sep. 30, 2019 $ 0 119,379,000 872,000 (99,849,000) 20,402,000
Ending balance (in shares) at Sep. 30, 2019 37,099,352        
Beginning balance at Dec. 31, 2019 $ 0 119,468,000 872,000 (105,431,000) 14,909,000
Beginning balance (in shares) at Dec. 31, 2019 37,099,352        
CHANGES DURING THE YEAR:          
Share-based compensation $ 0 264,000 0 0 264,000
Net loss       (7,016,000) (7,016,000)
Ending balance at Jun. 30, 2020 $ 0 119,732,000 872,000 (112,447,000) 8,157,000
Ending balance (in shares) at Jun. 30, 2020 37,099,352        
CHANGES DURING THE YEAR:          
Share-based compensation $ 0 (357,000) 0 0 (357,000)
Net loss       (2,449,000) (2,449,000)
Ending balance at Sep. 30, 2020 $ 0 $ 119,375,000 $ 872,000 $ (114,896,000) $ 5,351,000
Ending balance (in shares) at Sep. 30, 2020 37,099,352        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares
Sep. 30, 2020
Sep. 30, 2019
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY    
Common Stock, No Par Value $ 0 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Operating activities:    
Net loss $ (9,465) $ (21,520)
Adjustments required to reconcile net loss to net cash used in operating activities:    
Financing costs, net 0 4,652
Depreciation 77 70
Gain on sale of property and equipment (19) 0
Share-based payments (93) 1,069
Write-off of right-of-use related to restructuring 85 0
Changes in operating asset and liabilities:    
Prepaid and other current 16 4,823
Other non-current assets 5 70
Trade payables (393) 913
Accrued expenses and other (1,235) (621)
Net cash used in operating activities (11,022) (10,544)
Investing activities:    
Purchase of property and equipment (34) (346)
Proceeds from sale of property and equipment 119 0
Net cash provided by (used in) investing activities 85 (346)
Financing activities:    
Proceeds from issuance of ordinary shares and warrants 0 30,500
Issuance costs 0 (3,879)
Net cash provided by financing activities 0 26,621
Increase (decrease) in cash, cash equivalents and restricted cash (10,937) 15,731
Cash, cash equivalents and restricted cash at, beginning of period 17,705 7,640
Cash, cash equivalents and restricted cash at, end of period $ 6,768 $ 23,371
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Reconciliation in amounts on consolidated balance sheets:    
Cash and cash equivalents $ 6,768 $ 23,241
Restricted cash 0 130
Total cash, cash equivalents and restricted cash 6,768 23,371
Supplemental disclosure of cash flow information:    
Reclassification of warrants due to reassessment 0 3,628
Reclassification of warrants due to modification 0 8,198
Taxes paid in cash 0 605
Interest paid in cash $ 0 $ 4
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
The Company and Basis of Presentation
9 Months Ended
Sep. 30, 2020
The Company and Basis of Presentation  
The Company and Basis of Presentation

1. The Company and Basis of Presentation

Anchiano Therapeutics Ltd. is an early-stage preclinical biopharmaceutical company committed to discovering and developing new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies. The Company is developing small-molecule pan-mutant RAS inhibitors and inhibitors of PDE10 and the β-catenin pathway.

In November 2019, the Company discontinued clinical development of inodiftagene vixteplasmid. After a thorough evaluation of the available data, the Company determined there was a low probability of surpassing the pre-defined futility threshold at the planned interim analysis of its Phase 2 Codex study, which was evaluating inodiftagene vixteplasmid in patients with BCG-unresponsive non-muscle-invasive bladder cancer (“NMIBC”), and announced the discontinuation of the study.

In January 2020, the Board of Directors of the Company approved management’s recommendation to close the Company’s office and laboratories located in Israel. Following the closure of the Israeli facilities at the end of May 2020, the Company’s sole remaining office is located in Cambridge, Massachusetts (for details, see Note 4 below).  The Company currently maintains the lease on this facility in good standing and is also assessing the ability of the staff to continue working remotely under the restrictions of COVID-19.  

In March 2020 the World Health Organization declared the global novel coronavirus (COVID-19) outbreak a pandemic. As of October 14, 2020, the Company’s operations have not been significantly impacted by the COVID-19 outbreak. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including ongoing and planned pre-clinical development activities.

On July 2, 2020, the Company’s Chief Executive Officer Dr. Frank Haluska sent a letter to the Company’s Chairman outlining Dr. Haluska’s belief that events had occurred that were sufficient to trigger his ability to resign for “Good Reason” under his employment agreement. The Board informed Dr. Haluska that it disagreed with the letter’s assertions regarding “Good Reason” and treated the letter as a constructive resignation effective as of July 2, 2020. On July 12, 2020, Dr. Frank Haluska tendered his written resignation from the Company’s Board of Directors, effective immediately. Dr. Haluska referenced the matters articulated in his letter of July 2, 2020, and the Company’s response and actions following receipt of the letter as the basis for his resignation from the Board. It is the Company’s position, based on its legal counsel, that the CEO resigned without Good Reason, is not entitled to severance, and the Company will contest any and all claims for severance. Prior to the appointment of Mr. Neil Cohen as CEO in October 2020 (see below) the Board handled all matters related to CEO duties.

On October 20, 2020, the Company appointed Mr. Neil Cohen as Chief Executive Officer of the Company, effective immediately.  Mr. Cohen will continue to serve as a member of the Company’s board of directors. The Company also appointed Andrew Fine to serve as the Chief Financial Officer of the Company, effective immediately. Mr. Fine previously served as the Company’s Interim Chief Financial Officer pursuant to a subcontracting agreement.

In light of business circumstances, and in order to conserve cash and preserve optionality while alternatives are being identified and assessed, the Company made a decision during July 2020 to undertake reductions in headcount and other cost saving measures. These include plans to temporarily reduce its internal and external research and development work on the Company's pan-RAS-inhibitor program until there is greater clarity regarding Anchiano's ability to fund the program.

The Company continues to undertake actions for the promotion of the program and its assets and towards strengthening the protection of all related intellectual property.

As a result of the above the Company took  charges associated with severance and, discontinuation of external clinical development activities,. These charges amounted to $1.03 million for discontinuation of external clinical development activities and $0.5 million for severance (see Notes 6 and 7 below).

The Company is incorporated and registered in Israel. The Company’s American Depositary Shares ("ADSs"), each representing five ordinary shares of the Company with no par value (the "ordinary shares"), began trading on the Nasdaq Capital Market (“Nasdaq”) in February 2019 under the symbol "ANCN". The Company’s ordinary shares traded on the Tel Aviv Stock Exchange (“TASE”) between August 2006 and June 2019, at which time the Company voluntarily delisted from the TASE. The Company wholly owns a subsidiary, Anchiano Therapeutics Israel Ltd., which itself wholly owns a Delaware-incorporated subsidiary, Anchiano Therapeutics, Inc.

Liquidity

The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company has incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit at September 30, 2020 of $114.9 million. The Company has financed operations to date primarily through public and private placements of equity securities. The Company anticipates that it will continue to incur net losses for the foreseeable future. The Company believes that its existing cash and cash equivalents will only be sufficient to fund its projected cash needs into the first quarter of 2021. Accordingly, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. To meet future capital needs, the Company would need to raise additional capital through equity or debt financing or other strategic transactions. However, any such financing may not be on favorable terms or may not be available to the Company on any terms. The failure of the Company to obtain sufficient funds on commercially-acceptable terms when needed, would have a material adverse effect on the Company’s business, results of operations and financial condition. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of the Company’s expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company’s expenses could prove to be significantly higher than it currently anticipates. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Unaudited Interim Financial Information

The interim condensed consolidated financial statements included in this quarterly report are unaudited. The unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for a fair statement of the Company’s financial position as of September 30, 2020, and its results of operations for the three and nine months ended September 30, 2020 and 2019, changes in shareholders’ equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other future annual or interim period. The December 31, 2019 balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Form 10‑K for the year ended December 31, 2019 as filed with the SEC. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2019 included in the Company’s Form 10‑K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

a.    Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis, including those related to share-based compensation, leases and derivatives. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

b.    Reclassifications

Certain prior year amounts shown in the accompanying unaudited condensed consolidated financial statements have been reclassified to conform to the 2020 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total shareholders’ equity, net loss, or loss per share.

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued expenses and other
9 Months Ended
Sep. 30, 2020
Accrued expenses and other  
Accrued expenses and other

3. Accrued expenses and other

Accrued and other current liabilities consist of the following for the periods indicated (in thousands):

 

 

 

 

 

 

 

 

 

    

September 30, 

    

December 31, 

 

    

2020

    

2019

Accrued expenses

 

$

1,361

 

$

372

Restructuring accrual

 

 

238

 

 

2,161

Payroll and related

 

 

21

 

 

60

Liability for employee rights upon retirement

 

 

 —

 

 

262

 

 

$

1,620

 

$

2,855

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
9 Months Ended
Sep. 30, 2020
Leases  
Leases

4. Leases

In January 2018, the Company signed an agreement to rent a laboratory and offices in Jerusalem through May 2023. The Company had an option to extend the agreement by another five years. The annual rent (including management fees) is approximately $0.4 million and is linked to the Israeli Consumer Price Index. Pursuant to the agreement, bank guarantees of $0.1 million were provided to the property owner. In January 2020, pursuant to the Company’s decision to close its Israeli operations, the agreement was modified such that the Company vacated the facilities on May 30, 2020 but will continue to make scheduled lease payments through October 31, 2020. The Company recorded restructuring expense of $247,000 related to the modification of the Israeli lease agreement and settled all obligations associated with the lease.

In May 2018, the Company signed an agreement to rent space for its headquarter offices in Cambridge, Massachusetts. This agreement was amended in October 2019 to reflect relocating to a new 2,400 square foot suite within the same facility effective February 1, 2020. The annual rent is approximately $0.2 million. The amended lease term ends January 31, 2022 and there are no options to extend the lease.

The Company currently maintains the lease in good standing and is assessing the ability of the staff to continue working remotely under the restrictions of COVID-19. .

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
License Agreement
9 Months Ended
Sep. 30, 2020
License Agreement  
License Agreement

5. License Agreement

In September 2019, the Company announced that it entered into an option to license agreement with ADT Pharmaceuticals, LLC (“ADT”). Pursuant to the terms and conditions set forth in the agreement, the parties agreed to conduct research and development activities of novel small-molecule inhibitors (RAS and PDE10/β-catenin). As part of the arrangement, the Company is primarily responsible for the research, development, manufacturing and regulatory activities and ADT assists with the research activities as necessary in exchange for a quarterly fee from the Company. In connection with the agreement, ADT also granted the Company exclusive rights to research, develop, manufacture and commercialize the aforementioned compounds relating to patents owned by ADT and any products containing such compounds worldwide. In consideration for the rights granted under the agreement, the Company committed to pay ADT (i) a $3 million upfront fee; (ii) a fee upon transfer of the know-how and intellectual property rights to the Company; and then (iii) additional payments, including milestone and royalty payments. The Company has the ability to terminate the agreement at any time in its entirety or on a compound-by-compound basis after providing 90 days written notice to ADT. The upfront fee was paid in the third quarter of 2019. The Company accounted for the upfront fee and additional payments as a research and development expenses and continues to make ongoing payments to ADT in support of its maintenance of the Company's assets.

 

In April 2020, the Company notified Yissum Technology Transfer Company of the Hebrew University Ltd. (“Yissum”) that as a result of the Company’s previous decision to discontinue clinical development of inodiftagene, it will cease payments to maintain intellectual property (“IP”) it licensed from Yissum that supported the development and as related to a licensing and development agreement between the parties (“License Agreement”). In August 2020 the Company agreed with Yissum on termination of  the License Agreement, the Company destroyed or returned all IP documentation to Yissum and Yissum and the Company mutually waived, released and discharged the other from all claims of any type.

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring
9 Months Ended
Sep. 30, 2020
Restructuring  
Restructuring

6. Restructuring

Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication has been made to those affected.

The Company has recorded restructuring expenses related principally to contract termination costs due to the discontinuation of the clinical trials to CROs and manufacturers and contractual involuntary termination benefits to employees which have been accounted for as ongoing benefit arrangements and associated termination costs related to the reduction of its workforce.

One-time termination benefits are expensed at the date the employees are notified, unless the employees must provide future services beyond a minimum retention period, in which case the benefits are expensed ratably over the future service periods. A provision for contract termination costs, in which a contract is terminated or the entity will continue to incur costs pursuant to contract for its remaining term without economic benefit, is recognized only when the contract is terminated or when the entity permanently ceases using the rights granted under the contract.

In November 2019, the Company decided to discontinue its Phase 2 Codex study in patients with BCG-unresponsive NMIBC. In connection with this decision, the Company is required to make certain payments under contracts with CROs and with manufactures of the drug in order to terminate the contracts and close the trials. This restructuring plan included a reduction in the workforce of seven employees.

In January 2020, the Board of Directors approved management’s recommendation to close the Company’s office and laboratories located in Israel. In connection with this restructuring, the employment of the remaining five Israeli employees was terminated in the second quarter of 2020.

As noted above, in conjunction with this decision the Company renegotiated its lease for Israeli laboratory and office space. In connection with this decision, the Company vacated the facilities on May 31, 2020 but will continue to make scheduled lease payments through October 31, 2020. In the first quarter of 2020, the Company recorded a restructuring charge to adjust its operating lease right of use asset and operating lease liability to reflect the loss on the early termination of the Israeli lease obligation.

The following table represents a roll forward of the restructuring and other activities noted above (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

CRO,

    

 

 

    

Facility 

    

 

 

 

 

 Manufacturing

 

Severance-

 

and 

 

 

 

 

    

 and other related

    

related

    

Leases

    

Total

Balance, January 1, 2020

 

$

2,572

 

$

336

 

$

 —

 

$

2,908

Expenses

 

 

 502

 

 

 —

 

 

247

 

 

 749

Paid or consummed

 

 

(2,835)

 

 

(336)

 

 

(247)

 

 

(3,138)

Balance, September 30, 2020

 

$

238

 

$

 —

 

$

 —

 

$

238

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Research and development
9 Months Ended
Sep. 30, 2020
Research and development  
Research and development

7. Research and development

As noted above, and in conjunction with the Company’s decision to reassess its strategy around research and development efforts of its scientific and assets,  in the third quarter the Company took  charges associated with severance and, discontinuation of clinical development activities,. These charges amounted to $1.03 million for discontinuation of clinical development activities and $0.5 million for severance of research and development personnel.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity
9 Months Ended
Sep. 30, 2020
Shareholders' Equity  
Shareholders' Equity

8. Shareholders’ Equity

a.

2018 Private Placement

In June 2018, the Company completed a $22.9 million fundraising round from investors in the United States and Israel. In consideration for the investment, the Company issued 5,960,787 ordinary shares at a price per share of approximately $3.842, as well as 2,713,159 warrants to acquire additional shares equal to 80% of the shares issued, at an exercise price per share of NIS 16.20 (approximately $4.32). The warrants are exercisable for five years from December 31, 2018, the closing date of the transaction, and may be exercised on a cashless basis.

In addition, the investors were granted price protection rights (to shares and warrants) in the event of a future share issuance by the Company wherein the price does not increase by at least approximately 42.86% over the price per share in the fundraising (or is less than the adjusted price per share, if the price has already been adjusted). For details of an allocation that took place in 2019 pursuant to these rights, see Note 7b below. The warrants and shares were recorded within equity on the issuance date.

Effective January 1, 2019, the Company changed its functional currency from NIS to USD. Due to this change, the exercise price of the warrants was no longer denominated in the Company’s functional currency and therefore not considered indexed to the Company’s own shares according to ASC 815‑40. Accordingly, the Company recorded the fair value of the warrants as a liability at January 1, 2019.

Subsequently, upon the Company’s Nasdaq initial public offering on February 14, 2019, the warrants’ term was modified such that the exercise price currency was changed to USD. As a result, the warrants were once again considered indexed to the Company’s own shares according to ASC 815‑40. Accordingly, the fair value of the warrants at February 14, 2019 was reclassified from a liability to equity on that date.

The following table summarizes the activity for the warrants whose fair value measurements are estimated utilizing Level 3 inputs:

 

 

 

 

 

 

    

2019

Fair value on January 1, 2019

 

$

3,628

Adjustments-finance expenses

 

 

4,570

Fair value on February 14, 2019

 

$

8,198

 

 

 

 

 

The Company has determined the fair value of the warrants (a Level 3 valuation) as of January 1, 2019 and February 14, 2019. The fair value of these warrants was estimated by implementing the Probability-Weighted Expected Return Method or the Black-Scholes Method. The following parameters were used:

 

 

 

 

 

 

 

 

 

 

    

Derivative Financial Instrument

 

 

    

February 14, 2019

    

January 1, 2019

 

 

 

 

 

 

 

 

 

Share price

 

$

1.84

 

$

2.50

 

Expected term

 

 

End of 2022

 

 

End of 2022

 

Risk free rate

 

 

2.49

%  

 

1.37

%

Volatility

 

 

52

%  

 

48

%

 

b.

Public Offering

On February 14, 2019, the Company raised gross proceeds of $30.5 million in its Nasdaq initial public offering (“IPO”), allocating 2,652,174 ADSs, each representing five ordinary shares of the Company. The ADSs are listed under the symbol “ANCN.” In accordance with price protection rights granted in 2018 and activated in the offering (see Note 7a above for details and accounting treatment), the Company issued an additional 8,262,800 ordinary shares (equivalent to 1,652,560 ADSs) to rights holders and adjusted their warrants to be exercisable for an additional 6,207,330 ordinary shares (equivalent to 1,241,466 ADSs).

c.

Share-based compensation

The Company has two share-based compensation plans under which share options or other share-based awards have been granted: the 2011 Share Option Plan and the 2017 Share Option Plan (the “2017 Plan”). The 2017 Plan replaced the 2011 Share Option Plan with respect to future grants; and, therefore, no further awards may be made under 2011 Share Option Plan. The Compensation Committee of the Board of Directors and the Board of Directors administer these plans.

The fair value of each option granted is estimated using the Black-Scholes option pricing method. The volatility is based on the Company’s historical volatility. The risk-free interest rate assumption is based on observed Treasury yields over the expected term of the options granted with USD-denominated exercise prices (options granted in the past with NIS-denominated exercise prices used the equivalent Israeli government bond yields). The Company’s management uses the mid-point between the vesting date and the contractual term for each vesting tranche or its expectations, as applicable, of each option as its expected term. The expected term of the options granted represents the period of time that granted options are expected to remain outstanding

The fair value of each option granted in the nine months ended September 30, 2019 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:

 

 

 

 

 

    

Nine months ended

 

 

September 30, 2019

Value of ordinary share

 

$1.03 - $1.54

Dividend yield

 

0%

Expected volatility

 

51.5% - 68.6%

Risk-free interest rate

 

2.2% - 2.5%

Expected term (years)

 

5.5 - 6.9

 

The fair value of each option granted in the nine months ended September 30, 2020 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:

 

 

 

 

 

    

Nine months ended

 

 

September 30, 2020

Value of ordinary share

 

$0.15 - $0.17

Dividend yield

 

0%

Expected volatility

 

64.9% - 67.4%

Risk-free interest rate

 

0.30% to 0.39%

Expected term (years)

 

5.5 - 6.5

 

The following table summarizes the number of options outstanding and exercisable as of September 30, 2020:

 

 

 

 

 

 

 

 

 

 

    

 

    

 

 

    

Weighted Average 

 

 

 

 

Weighted 

 

Remaining 

 

 

Number of 

 

Average 

 

Contractual Life in 

 

    

Shares

    

Exercise Price

    

Years

Options outstanding - January 1, 2020

 

3,822,374

 

$

2.50

 

8.5

Granted

 

885,000

 

 

 

 

 

Forfeited/expired/cancelled

 

(1,578,031)

 

 

  

 

  

Options outstanding - September 30, 2020

 

3,129,343

 

$

2.44

 

7.9

Options exercisable - September 30, 2020

 

2,389,840

 

$

3.01

 

7.5

 

The aggregate intrinsic value of both outstanding and exercisable options at September 30, 2020 is $0.

The following table illustrates the effect of share-based compensation on the statements of operations (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

    

Nine months ended

 

 

September 30, 

 

September 30, 

 

 

2020

    

2019

    

2020

    

2019

Research and development

 

$

(290)

 

$

154

 

$

(166)

 

$

438

General and administrative

 

 

(67)

 

 

168

 

 

70

 

 

632

 

 

$

(357)

 

$

322

 

$

(96)

 

$

1,070

 

The negative amounts for both Research and development and General and administrative reflect the forfeiture of vested stock options and the reversal of accrued compensation on account of future vesting on stock options that were granted to employees who were terminated as part of the Company's restructuring activities as mentioned above.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per share
9 Months Ended
Sep. 30, 2020
Net Loss per share  
Net Loss per share

9. Net Loss per share

Basic loss per share is computed on the basis of the net loss for the period divided by the weighted-average number of ordinary shares outstanding during the period. Diluted loss per share is based upon the weighted-average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options which are included under the treasury stock method when dilutive.

The following ordinary shares underlying stock options and warrants were excluded from the calculation of diluted net loss per ordinary share, because their effect would have been anti-dilutive for the three and nine month periods presented:

 

 

 

 

 

 

 

 

September 30

 

 

2020

    

2019

Stock Options

 

3,129,343

 

3,985,858

Warrants

 

10,975,959

 

10,975,959

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Use of Estimates

a.    Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis, including those related to share-based compensation, leases and derivatives. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

Reclassification

b.    Reclassifications

Certain prior year amounts shown in the accompanying unaudited condensed consolidated financial statements have been reclassified to conform to the 2020 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total shareholders’ equity, net loss, or loss per share.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued expenses and other (Tables)
9 Months Ended
Sep. 30, 2020
Accrued expenses and other  
Accrued and other current liabilities

Accrued and other current liabilities consist of the following for the periods indicated (in thousands):

 

 

 

 

 

 

 

 

 

    

September 30, 

    

December 31, 

 

    

2020

    

2019

Accrued expenses

 

$

1,361

 

$

372

Restructuring accrual

 

 

238

 

 

2,161

Payroll and related

 

 

21

 

 

60

Liability for employee rights upon retirement

 

 

 —

 

 

262

 

 

$

1,620

 

$

2,855

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring (Tables)
9 Months Ended
Sep. 30, 2020
Restructuring  
Schedule of roll forward of the restructuring and other activities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

CRO,

    

 

 

    

Facility 

    

 

 

 

 

 Manufacturing

 

Severance-

 

and 

 

 

 

 

    

 and other related

    

related

    

Leases

    

Total

Balance, January 1, 2020

 

$

2,572

 

$

336

 

$

 —

 

$

2,908

Expenses

 

 

 502

 

 

 —

 

 

247

 

 

 749

Paid or consummed

 

 

(2,835)

 

 

(336)

 

 

(247)

 

 

(3,138)

Balance, September 30, 2020

 

$

238

 

$

 —

 

$

 —

 

$

238

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Tables)
9 Months Ended
Sep. 30, 2020
Shareholders' Equity  
Summary of the activity for the warrants whose fair value measurements are estimated utilizing Level 3 inputs

 

 

 

 

 

    

2019

Fair value on January 1, 2019

 

$

3,628

Adjustments-finance expenses

 

 

4,570

Fair value on February 14, 2019

 

$

8,198

 

 

 

 

 

Summary of assumptions used in valuation of the fair value of the warrants

 

 

 

 

 

 

 

 

 

    

Derivative Financial Instrument

 

 

    

February 14, 2019

    

January 1, 2019

 

 

 

 

 

 

 

 

 

Share price

 

$

1.84

 

$

2.50

 

Expected term

 

 

End of 2022

 

 

End of 2022

 

Risk free rate

 

 

2.49

%  

 

1.37

%

Volatility

 

 

52

%  

 

48

%

 

Summary of assumptions used in valuation of the fair value of the options granted

The fair value of each option granted in the nine months ended September 30, 2019 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:

 

 

 

 

 

    

Nine months ended

 

 

September 30, 2019

Value of ordinary share

 

$1.03 - $1.54

Dividend yield

 

0%

Expected volatility

 

51.5% - 68.6%

Risk-free interest rate

 

2.2% - 2.5%

Expected term (years)

 

5.5 - 6.9

 

The fair value of each option granted in the nine months ended September 30, 2020 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions:

 

 

 

 

 

    

Nine months ended

 

 

September 30, 2020

Value of ordinary share

 

$0.15 - $0.17

Dividend yield

 

0%

Expected volatility

 

64.9% - 67.4%

Risk-free interest rate

 

0.30% to 0.39%

Expected term (years)

 

5.5 - 6.5

 

Summary of outstanding and exercisable options

 

 

 

 

 

 

 

 

 

    

 

    

 

 

    

Weighted Average 

 

 

 

 

Weighted 

 

Remaining 

 

 

Number of 

 

Average 

 

Contractual Life in 

 

    

Shares

    

Exercise Price

    

Years

Options outstanding - January 1, 2020

 

3,822,374

 

$

2.50

 

8.5

Granted

 

885,000

 

 

 

 

 

Forfeited/expired/cancelled

 

(1,578,031)

 

 

  

 

  

Options outstanding - September 30, 2020

 

3,129,343

 

$

2.44

 

7.9

Options exercisable - September 30, 2020

 

2,389,840

 

$

3.01

 

7.5

 

Summary of the effect of share-based compensation on the statements of operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended

    

Nine months ended

 

 

September 30, 

 

September 30, 

 

 

2020

    

2019

    

2020

    

2019

Research and development

 

$

(290)

 

$

154

 

$

(166)

 

$

438

General and administrative

 

 

(67)

 

 

168

 

 

70

 

 

632

 

 

$

(357)

 

$

322

 

$

(96)

 

$

1,070

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per share (Tables)
9 Months Ended
Sep. 30, 2020
Net Loss per share  
Schedule of share options and warrants were excluded from the calculation of diluted net loss per ordinary share because their effect would have been anti-dilutive for the years presented

 

 

 

 

 

 

 

September 30

 

 

2020

    

2019

Stock Options

 

3,129,343

 

3,985,858

Warrants

 

10,975,959

 

10,975,959

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
The Company and Basis of Presentation (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Oct. 20, 2020
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Restructuring Cost and Reserve [Line Items]        
Severance expense     $ (3,138)  
Number of ordinary shares represented by each ADS (in shares)     5  
Ordinary shares, par value (in dollars per share)   $ 0 $ 0 $ 0
Accumulated deficit   $ 114,900 $ 114,900  
Discontinuation of external clinical development        
Restructuring Cost and Reserve [Line Items]        
Discontinuation costs $ 1,030 1,030    
Severance-Related        
Restructuring Cost and Reserve [Line Items]        
Severance expense   $ 500 $ (336)  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued expenses and other (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Accrued expenses and other    
Accrued expenses $ 1,361 $ 372
Restructuring accrual 238 2,161
Payroll and related 21 60
Liability for employee rights upon retirement   262
Total $ 1,620 $ 2,855
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2018
USD ($)
May 31, 2018
Jan. 31, 2018
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
Feb. 01, 2020
ft²
Leases            
Option for extend agreement     5 years      
Annual rent including management fees $ 200   $ 400      
Bank guarantees provided to property owner     100      
Restructuring expenses     $ 247 $ 79 $ 749  
Area of land | ft²           2,400
Options to extend the lease   false        
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
License Agreement (Details)
$ in Millions
1 Months Ended
Sep. 30, 2019
USD ($)
License Agreement  
Upfront fee for license arrangements $ 3
Written notice period for termination of the agreement 90 days
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Restructuring    
Beginning balance   $ 2,908
Expenses   749
Paid or consumed   (3,138)
Closing balance $ 238 238
CRO, manufacturing and other related    
Restructuring    
Beginning balance   2,572
Expenses   502
Paid or consumed   (2,835)
Closing balance 238 238
Severance-Related    
Restructuring    
Beginning balance   336
Paid or consumed $ 500 (336)
Facilities and Leases    
Restructuring    
Expenses   247
Paid or consumed   $ (247)
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Research and development (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 20, 2020
Sep. 30, 2020
Sep. 30, 2020
Restructuring Cost and Reserve [Line Items]      
Severance expense     $ (3,138)
Discontinuation of external clinical development      
Restructuring Cost and Reserve [Line Items]      
Discontinuation costs $ 1,030 $ 1,030  
Severance-Related      
Restructuring Cost and Reserve [Line Items]      
Severance expense   $ 500 $ (336)
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity - 2019 Public offering and 2018 Private Placement (Details)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended 12 Months Ended
Feb. 14, 2019
USD ($)
shares
Jun. 30, 2018
USD ($)
$ / shares
shares
Sep. 30, 2020
shares
Dec. 31, 2018
Jun. 30, 2018
₪ / shares
Jun. 30, 2018
$ / shares
Sale Of Stock [Line Items]            
Number of ordinary shares represented by each ADS (in shares)     5      
2019 Public offering            
Sale Of Stock [Line Items]            
Initial public offering cost | $ $ 30.5          
Number of ADSs issued 2,652,174          
Number of ordinary shares represented by each ADS (in shares) 5          
Number of ordinary shares issued 8,262,800          
Number of equivalent ADS for ordinary shares 1,652,560          
Additional warrants exercisable 6,207,330          
Number of equivalent ADS for warrants 1,241,466          
2018 Private Placement            
Sale Of Stock [Line Items]            
Number of warrants issued   2,713,159        
Number of ordinary shares issued   5,960,787        
Proceeds from issuance of shares | $   $ 22.9        
Share price per share | $ / shares   $ 3.842        
Percentage of additional share issued, to be acquired by warrants.   80.00%        
Warrant exercise price | (per share)         ₪ 16.20 $ 4.32
Warrants exercisable period       5 years    
Threshold percentage for future share issuance price     42.86%      
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity - Warrants activity (Details)
$ in Thousands
2 Months Ended
Feb. 14, 2019
USD ($)
Shareholders' Equity  
Fair value at the beginning of the year $ 3,628
Adjustments- finance expenses 4,570
Fair value at the end of the year $ 8,198
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity - Fair Value assumptions of warrants and 2018 Reverse Split (Details)
Sep. 30, 2020
shares
Dec. 31, 2019
shares
Feb. 14, 2019
$ / shares
Jan. 01, 2019
$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
Ordinary shares, shares authorized | shares 500,000,000 100,000,000    
Stock price (USD)        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
Derivative Liability, Measurement Input | $ / shares     1.84 2.50
Risk free rate        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
Derivative Liability, Measurement Input     2.49 1.37
Volatility        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
Derivative Liability, Measurement Input     52 48
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity - Fair value of stock options (Details) - 2011 share option plan
9 Months Ended
Sep. 30, 2020
plan
$ / shares
Sep. 30, 2019
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Dividend yield 0.00% 0.00%
Expected volatility, minimum 64.90% 51.50%
Expected volatility, maximum 67.40% 68.60%
Risk-free interest rate, minimum 0.30% 2.20%
Risk-free interest rate, maximum 0.39% 2.50%
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Value of ordinary share $ 0.15 $ 1.03
Expected term 5 years 6 months 5 years 6 months
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Value of ordinary share $ 0.17 $ 1.54
Expected term 6 years 6 months 6 years 10 months 24 days
Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of share based compensation plans | plan 2  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity - Summary of outstanding and exercisable options (Details) - Stock Options - 2011 share option plan - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Share-based compensation    
Aggregate intrinsic value $ 0.0  
Number of options    
Outstanding at the beginning 3,822,374  
Granted 885,000  
Forfeited (1,578,031)  
Outstanding at the end 3,129,343 3,822,374
Options exercisable 2,389,840  
Weighted Average Exercise Price    
Outstanding at the beginning $ 2.50  
Outstanding at the end 2.44 $ 2.50
Options exercisable $ 3.01  
Weighted Average Remaining Contractual Life in Years    
Weighted Average Remaining Contractual Life in Years 7 years 10 months 24 days 8 years 6 months
Options exercisable 7 years 6 months  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity - Share-based compensation expenses (Details) - 2011 share option plan - Stock Options - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expenses $ (357) $ 322 $ (96) $ 1,070
Research and development expenses        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expenses (290) 154 (166) 438
General and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expenses $ (67) $ 168 $ 70 $ 632
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per share - Severance pay and Antidilutive securities (Details) - shares
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Stock Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 3,129,343 3,985,858
Derivative Financial Instruments - Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 10,975,959 10,975,959
EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "Q0<%$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " L4'!1)P%6@^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$Y9#R;-96.G%@8K;.QF;+4UB_]@:R1]^SE9FS*V!]C1TL^? M/H%:':4."9]3B)C(8KX;7>^SU''#3D11 F1]0J=R71*^- \A.47EF8X0E?Y0 M1X2&\S4X)&44*9B 55R(K&N-ECJAHI N>*,7?/Q,_0PS&K!'AYXRB%H ZZ:) M\3SV+=P $XPPN?Q=0+,0Y^J?V+D#[)(621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M "Q0<%% )"(9+00 !(/ 8 >&PO=V]R:W-H965T&UL MC9==<^(V%(:OM[]"PU4[$_ 7)+ #S #9M)EV:3:D[>QT>B'L ];$EKR2#.'? M]\@V-LD8P0U8ML[K1T?R*YWQ7LA7%0-H\I8F7$TZL=;99\=180PI53V1 <EC'>FX^+>DYR.1:X3QN%)$I6G*96'.21B M/^EXG>.-9[:-M;GA3,<9W<(*]%_9D\264ZM$+ 6NF.!$PF;2F7F?%WX14/3X MF\%>G5P3,Y2U$*^F\1A-.JXA@@1";20H_NU@ 4EBE)#C1R7:J=]I D^OC^H/ MQ>!Q,&NJ8"&2?UBDXTEGV"$1;&B>Z&>Q_PVJ 0V,7B@25?R2?=FWCV\, MJ&8NBMP4T3@:QLTTKK3$IPSC]/1>A#G.BB:41^0+UTP?R",OEX=)HF$I0 M8T?CVTR,$U;*\U+9/Z,\(E\%U[%"U0BB]_$.4M:H_A%U[EL%5Y#U2.#>$-_U MW1:>A3U\*78]XMVVA;_#">K,!85><$9O(78@R;^SM=(2%^-_%LE^+=DO)/N7 M)N/ED$%;QNWAGMO]9J$8U!2#ZRB>0#)A5D5$<&VU MF5CC/VTZ=/%Y)^6[/= M6A6K%?H,6V;2CI!+FK:2V75F/(P9Y8*\Q"!I!KEFH2)_Z*AG@;RK(>^LXB^2 M1HQOR>J0KD72!F>/GRT72PO&L,887I.K12ZEFF.F_]HNV"WS_: MP#NL48TUN@;KD6N0I8F;U46/G&U8=D$[EN _; $ORN%[C@MT(>6GW/ MKK,4O$O#$'=S:BRVCM(U6++O:AB;*RM58LQ=N,^97O F^T>81>[L&%[C=U[=GO^2%6=*LYSV>6^!;:C9&/VOMVD9X@4E5@) M;5O=\PL"E[Y OW%UW^[&+TPG0,2&>/[/ZU_("L)3'$B&.V'Q MH&V@SDG588RV*,84"47.=5F U'?K@F]6E#E.T[VL%K]2X].*)+#!4+=WAYXB MRP*L;&B1%37,6FBLB(K+&(M6D*8#/M\(H8\-\X*Z#)[^#U!+ P04 " L M4'!1Z"S*4.0$ !0$@ & 'AL+W=O=J6]MMIT[SX[Q&FL!9RU3=/LKS^;I$"P MH;D/;0S,C)\9V\\S,-TS_D-L"9'@+<\*<3/:2KF[=AR1;DF.Q17;D4(]V3"> M8ZDN^8LC=IS@=>649PYRW=#),2U&LVEU[XG/IJR4&2W($P>BS'/,#WN+IRZBAKFI-"4%8 3C8WHUMX/4>^=J@L M_J%D+UICH%-9,?9#7WQ9WXQC> 369(/+3'YC^\_DE%"@XZ4L$]5_L#_9NB.0 MED*R_.2L$.2T./[BMU,A6@[0[W% )P=TJ8-W0DFX/MR 7[_] ?X!&@!GK>L%+A8BZDC%08=R4E/\]T=YT,]\RW) M[@IX[A@@%[D6]_FP^X*DRAUJ=YB/JGA>7_HEYZ20 M!I+@> MB.C5$;TJHM\7$8LM4+4!J1Z0GR5]Q9F:PEJK8ZBP"J4/W.LLC,)XZKRV*V(: MP2B(@MKJ#*9?P_0'83YQLL-T# M[)VB.#D&!9$VH*&)(>C M)G$=I!1#3(:!/FH(&))BQ>0$<5X@&MJF[#-I!3$ MAC(R("#/[\ T;2!,$CO.N,89#^/4VP\4K)A\O.2Q,7^ .A!-$QA'=H1)C3"Y M8$/VHTK,C1C&20>7:023*.@YS]!MB-R]B,HRBE'%E6P_U5=4PQ"H[@654%]FZ#1"S@L&,?B?E144P20YW4% MS6+EQWZ/Y,)&+."P6LQ9GE.I9>QXF%)6Z+*2(NU#:VJ!<:*&3,YQ-F(!XT&^ M6VXQ)UN6K0D7OU7:*P^#A->0/!QF^4>^IH5ZIP%"3R&4FC-%?QRH1JXDJA?& MI=PR3G\IV@E<=^P>_T[62AT VP#5YTJ2KY2>O3>[53%AG[UJ;$_F<*Q[VS\! M%4(36\5GI112#?3N]J*QFR1C+T!U -DW6S>H=?5,.3)6;\CDO.UNU JYPXV3 M:CXGZE4BQ3NJ3H0-V2E"I\?P#'*QV_EA3]>$&N%#P\)W5-3T "3'A5OS%]H(93P;92?>Q6IY/GQ M\\7Q0K)=]05@Q:1D>37<$M74<6V@GF\8D^\7^J-"_1%I]A]02P,$% @ M+%!P4< F.C-L @ M@8 !@ !X;"]W;W)K1%\YI[G?G"UZJH9-K75VXKDIS**@Z%164>&9%;4%8Z\<#N+60\$+7FK(2%)*HN"BJ?QL#%=NCTG.>- M6[;.M=EPXT%%UY" _EDM)$9NYY*Q DK%1$DDK(;.J'8 *<&R/$^-UZ.EU)(]Q=/[M_M[UC+TNJ8"+X M+Y;I?.A\P(>OTW!'XK\(\5!*T@L(TV9+:M*=4T'DBQ)=)DHYM9V-E8-7;#2O,K)EKB M788Z'4]NYM/9/)E-":Z2F^NKZ>@.@_'H>C2?S$AR.9O=)>3S@DHH=0Z:I91_ M(5_))^(2E>.N&K@:.8R;F[8UQTU-_XV:"52G)/!.B._YW@'YY'WY%%*4]XR\ M=[XO=['[;@1^-P+?^@7_Y6Y1QUVU.&'J4_(E5+U8>3P%4APYIV?!Z'_@OB( MQ#W@J .._@'XIM9*TS)CY?H0=70L]1&)#;6[$5(#4DO2NT@I58=MG%PR)EMAGL<^YF2P9_RGR B1Z+TLJ!CV,BDW=Y8E%ADIL;AE&T+AS8KQ$DN8 M\K4E-IS@I38J"\NU[= J<4Y[HX%>>^&C =O*(J?DA2.Q+4O,?SV0@NV'/:=W M6'C-UYE4"]9HL,%K,B/RV^:%P\QJO"SSDE"1,XHX60U[]\Y=ZF@#C?B>D[TX M&B-%Y8VQGVKRM!SV;)41*_]9.>TU,97@\/GA_U.2! MS!L69,R*'_E29L->OX>69(6WA7QE^R^D)A0H?PM6"/T?[6NLW4.+K9"LK(TA M@S*GU1._UT(<&8 ?LX%;&[AM _^,@5<;>-=&\&L#_]H(06V@J5L5=RU<@B4> M#3C;(Z[0X$T-M/K:&O3*J3HH,\GA;0YV3I)T,DL3!*/9].M3J$'JJ$W#,)>>B949D)E-(E61KLD\OV\05["\1I M%'(/"CVX%QW.R.86>?9GY-JN;XJP01=Q>\^HU77WOUSWA])8)@OL@0'!FH\AU<7QNXC*3I]%2> M0NU)W8*[D>,&[L#:'6])%Q0$87 *2KH@+[3C4U!J"N=&88,ZX1LT?(.+?/\A M%&0L-%V\A*K.A52R[HB)<>4K.$X!*+<8&T"1W6;!1:T<2 \2/S>E%37K1Q?3F3,)NL,[9-F48=<*[ M?M#2<-P%16YDMXAT0;'?]UN[T04YD>OY9K[]AF__(M_'G&*Z(.AC3A>L))\. MA#\C2HQ%U^]D<1.U*!L@CMVJR\0$:E=<%^.[_3,%%S>$XXN$)]!Q%4P(77% M&7JJ3#4[.Z*7393C3N'?N+[?2G9L0$5.V&_1-J!BOWT?I::(3N#:9NJ._?L7 MWKY(_@&+?%%=K7FQE61920&G'8D,YW?IJN1R=7(U(3T@L#QX[9:UE&K6!*^UCVZ@)K84EFU M EO]]5'QS/FZYP*5) 5A+)O(TB75WU\ M-9%LHQO5-R:A[=7##+Y]"%< >+]B3!XF*D#S-37Z#U!+ P04 " L4'!1 M7F3V9:D% #@&P & 'AL+W=OT616I)L>]JE/6COM!^SB2G1YH6+3=G]]^>$-"'8L>E= M^Z$0>&8\?F;&\Y!,]T7Y@VPPIN!GEN;D:K2A='LYF9!H@[.07!1;G+-OUD69 MA91=EL\3LBUQ&-=&63I!FF9-LC#)1[-I_=E#.9L6.YHF.7XH =EE65C^NL%I ML;\:P='K!\OD>4.K#R:SZ39\QBM,G[8/);N:M%[B),,Y28H"]^3H/:BV\KTH?E07=_'52*LBPBF.:.4B9"\O>([3M/+$XOBG<3IJ MUZP,C]^_>@_JS;/-? \)GA?IWTE,-UK^RYUW_<@N5H_LY:N_>%R!^P#,;Z\7G_T5 MN%N U>WUTK^]_^+YR]7OP/_SZ>[Q&QB#IY4'/OSV<3JA+*;*\R1JUK\YK(\& MUK\OXR1G)0W()BPQ$3B8RQT\A$D\3G(0A=N$AJG @2=W,-^5)X=C(T-A?'^@)@1S,YV%CV]$UFT,&/-)U-/,8UR-*;XG2WTC4 M!U9>A_+\>!9I!__F46#0-&W3UK>+3Z#QUL??/.O MEY>2ZC!;UZ9TTW>$[.J]%NMFJY] CD7E>F,J2\+D]H^L*B]<2?# TVI0(H(S M%NLQ8K6,6/^%D>-B$+%C\>% $^F6/1".W89C2\-9XB@-"4G8*7(XH5A8^[!D M1Q8E(-YA0 MV4#$$)H0-?F'F;&7F;"[ZL6XAA\\<#SS-G!(1G+%8CRJGI!#ZN4)#MPU^ M,)T%[8=X)->@-$0_CT]F^!^[G(TCK1Y'KE" 067?-Y#>R(*N9@KR)X *Y[@ M-W:1Y4 !7SP4,0WA#M/5B1XH5STG=)U,N(L0TMO@&" M6:@V_N%=XJ*M129X_7)*RY==L5))"'BIN;QXU=US%XEX$ BC1# M0\-T=9((RC61O+G5U/$"1-' M-X:::>BBDUJP/$NZY*3NM B4BY$W_>P2T\?+ GD^42<,D/;>AS7J1CJ2C_2W M'-9(/_>W-U(1_*1_J;F5L]R)!B\NLDGTA, N;I0 M0H(SENOSTLUN))_=TO86W!E@Y2H0%^<@^P%V(QS)1[A4BPW4J'I^"R"U%C,% M&>2AXO;F<:R]#<<5'8<\UM3-86V-NO&-Y./[;"TV0-W9LWMR]*RC>O;U-2R9 M<" @Q6MFJEW8S$=Y>)QTN*#%MG[\\;V@M,CJMQLZUZ3@N:E$_AV;RX"G^\5RTN<"Y#[ MHJ#BY189KX=.WSEN+/)MILP&"?R*;C%!]5C-AQ& Z67&^,\ET/71<(P@9ILHP4+T<,$3&#)&6\:?E=+I7&N!I M?&2_L[WK7E948LC9KWRMLJ'SS8$U;NB>J06O)]CV-&"M8(B+YN5/K<^G #ZEV< 7@OPW@L8M #K'&F4V;;&5-' %[P&8:HUFPFL M-Q:MN\E+\Q43)?1IKG$J"&?Q.(J3: PZ2F;WT_%HJ9-DJ9>'*%XF,+N#<#** M?T0)3&-()J-%-)G=CZ-%\A&BGX_3Y6_X-*<"2Y6ARE/*/L,7^ $9*9WI4^4 MEFE>1M)6TFTCR3LC*<&J!P/W CS7+I[@)B#MIS>*)LCZ\YW'!=6RYSD0^!=O)P:N); M%8U .2":6](DBE=VT%9)7!F315;BO0[CW5R,9@.4,PVM$CU M5W'XQ(X.38R]2*2J_(\.1UEO@*)":9$=E0%!QO/JESX? W&B ';<"N2H0-H* MXPX%_ZC@EXY6R$JWKJFFB[D4!R2--%@S@S(VI39XPW.3QI66\):#GEXL'^ZO M;^Y7-]<(1JN'SW?7ET\P63W!SY>;^Z<5>KA%R\O5)W3[^>'["@W1M]4U>O_N M WJ'>(Z>$E$HFL=J/M* QM@<1<>5KZJ52 X\RS>KXUD/'+^.K%_:\SOL/>R8I)KGVZI4N>9, MG??8'==VQZ7=<8?=>^CM5"AGQ"O-H-0T#;Q?#&?C8#(?[4_CX) B>&)BMG?@ MFM2X)KW^7L;_0;E"AVL%_?VSX)+%2 L81R*/>,I0?D1NGIIQ1%6""@5B4$GB M+\,5U+""WG#=\IS"\F W$DJK,[.R*W25EA:X:;NU'3(=T<4G#(%[&WN9T'S+5*M)E8(.-@61)(V9Z0JZ3ID;V=AN"]_J"X?4#'=%L&$,/.E% M=QE%LH#J9\]P*E508G7*G4@GCMV%^%8<'6(!P1U8&QK!_3QR_Q;"6.( ML4=(&[=+SIN,QQW(&XK!86__WN5[V%K>SJRXX0G<3Q2/A8P2V'?_CB2P@R7\ M<3L:3J&@(Q8-5>!^KGB4(F(L5F@C1?8_" X[",)B.(=01R.3AD)(/X74Y0=8 M]QP.S&C]@MX?:_$#_-DY=N$G;^ 0ATQWZ$E#(Z2?1IJ#V-O*D#2$0?Y$&*=) MY4H5L%"96"%C6%6^(&7."-7^Y> M89?'5"&3.9.:]TQ\7#WDS MOWTP=\CA2>AW.=4P$>EGHN6;T2.JS]":;7F>FS29G8Y)+F*G5S;]X##TK,W! M%@N#<5?U-QQ%^K^#_M(G9LX)O=Z$UC=N$ ;3MC.V%/']L)VATY[2>7^'S974_U9BIKLN^4 E94BAE&S#I?0PAP+*Z M@:HF6NS*2YRUT%IDY3!A<+:31@#>;X30KQ.S0'T/N/@%4$L#!!0 ( "Q0 M<%&26">63@, , ) 8 >&PO=V]R:W-H965T&ULI5;; M;MLX$/T50NA#"W2CFRW;@6T@<1(T0-($D;M]9J2Q190B59**T[_OD')4-Y+E M!?;%XF7FS)F+9SC?2?5#%P"&O)91^% 2)7U(FO.7> MI?QA-[?YP@LL(^"0&0M!\?,"*^#<(B&/GWM0K[5I%0_7;^@WSGETYIEJ6$G^ MG>6F6'A3C^2PH34W3W+W!?8.C2U>)KEVOV37R$YF'LEJ;62Y5T8&)1/-E[[N M W&@@#C]"M%>(7JO,#JB$.\58N=HP\RY=44-7[VZF)]?472-7[NK[^N4_)P0U87Z1=R<_?P/24?'ZD" M80HP+*/\$_F'?$NOR,B*3&:=:LPUV"5?N:&Q'E:(V8GD-Q$@,&DJ UI997\2F M)U/=E8B3:-H?K5G+?/:_F99A\*>#!\-U2E]!DXJR MW+:78Y6X!QFBUR.2!.,C] X&3#A([U88L/^4TPS#3G?I,.R*C-[Q\P]F80EJ MZYX(&ELM-MUFBK2G[3/DP@W?=^>7]GGB9NP?F.9MU4*P\ "PG 8 >&PO=V]R:W-H965T&ULK5K9 M"G+3I[!&9"#" ., 0QIYNOOZ08P M'%*4$^?FQ=:00'>CE].G,7R\/N;/WOJGCUT?C;;JK1>A;UOI MU\^4<:LG!R<'Y8-W>M%$^N#HZ>-.+M2UBA^ZMQY/1X.46K?*!NVL\&K^Y.#\ MY*=G9[2>%_RFU2J,_A9TDIES-_1P53\Y.":#E%%5) D2_RW5A3*&!,&,CUGF MP:"2-H[_+M)?\-EQEID,ZL*9WW4=FR<'/QZ(6LUE;^([MWJI\GF^(WF5,X'_ M%:NT]@$65WV(KLV;84&K;?I??LI^&&WX\?B.#:=YPRG;G12QE9/O5L) M3ZLAC?[@H_)N&*4Z>GRKL2\^?=\H<>':3MJUD+86SV300;BY>.M54#9* M\MWCHPA5M.&HRF*?);&G=XA]*%XY&YL@GMM:U=O[CV#B8.=IL?/9Z6<%7JMN M*AX<3\3I\>GQ9^0]&,[]@.4]^/?.O:7G;-!SQGK._FW_?E[LR53\+R4WW451"_QGHJL%I:H:0WZ\,048$"95U!DZZD$3/MND8B[RO>@T^J MK S_MSI&58OH1*U#Y9;*:[M@*VJU1*%W]&A1DI6TE?(BLG*M KX/>F'3WBC] M K"#+Z'9U7T5V?ZVA^U8L5 6&V(CHY!>B=JC?#VO:/H6EK?20!040.ZV.W08 MVQ&PT!RV#D#0&ZB2]I!4V"C>G5\+;1L]T]'YP/:/'LF5E\]/COES,O*;KQZ> M??_HL()U5EL(BLU*KJ?WKJQX#1^T,YST]/CDX817%V/80S9JV^-,@WNS?8"W M2(JT=;6>4Q"L$DO]*:K.R-!JA.E\'B%70J;SKE\T0BVEZ3FZM)-4R:741LYP MN!H8L*->83N 0_$9X,>5Q$D%P)B.4<* M\++8(+D:9VHA<^",M+1"6ZC1+7PES3HGHD8\WS: 3'$*SBY\/>PI+.H3LLE;".8AHJHPZU74K^;&9D M7<-S.07O?_/5CZ>GQX]>O[IZ=L%_GSSZ=L*QQ0E=8_R+Q ME5\S$B5?/W/2U[3P4J."2O*,HR [.'L)#4A0AF5E7$5UPQ<=16\5&8J7CB#()=HDL@>T<]V MI45:S&5%@241.:"P@Q:]DN,#[IH14$RPFYH^*J F$A2"K MI@\J(H3W024H+9&S82*"4JB>J,29F!%%^':[E*O>>SC+K 4IPQX;V"*C**_( M70W4YF.L2>_"N1K1@HL*)A'0F> $K%";_!YE?HJOG,_9^;E8F4[08IP3]L&" MWM8)R_!1B%XSK^!07[SY[>KR\.0AY\^[OS*)>72AID[AN_D%;_ MF2)= VV!;"GM%@;%:)#)P 78X)V52^U[N*L(_U: 5,W O&Y0OW!.K5I= 1_8 M@C=(.\*?D[/)9^(&+N=ELKJ17#<17E=6$"AK!%&RJS5V513&V3J)R18,!DS% M2[<"@OEMK*FHDF+*)#@]@KT1C-3P5/)QIRK2(A2JV\:)J/MDSD0@)>:],5EU M0OV]JH$ 6,;6PX4$,8 H:@+DY(9Q=N)(8!;P(ZO8B M,W-&+H_IO3>H_![..?V<@R\:K>;B^2>T&F*;X@U7AA>7'@7II;T1+P%XX4:* MP/*1QY'@G;KA7G%2>^IUB4Z3W20IRQB6H7!(+3L-UA-.-A(.J+AZZO3%BL _ M]&0002FK]'JQ@'8*5BD'?.RY1PLJTPR:/U--O4/).9NA,Q<#[51M9]PZ^6OA M%8-;*N*$B]K2[ S1J8GDW0DM.5-=4+V5-KDDN%P5+4^Y:Q7"P@D+]QM%S=K M)$K,=94=S$T/^8&Z[7D0R*=,E:CF M67GB1W9+Q=R[=F^,;S>/R<@>C\_/YYV* MJTBXO$]_YX).H$#C5EW*W"#X5.(]3#.3$4(\?Y,5Y21"K8A18DQ(#\$2TE)' MDZAG(/ B8G#+#0E?J D XT4AUY(^,U*WZ7##]BG8MG9#_:+- UQB876O$*_7 M2AO(;I .\!$9B[ 4M.8F<9]:8.I](S;10"T92YI+<+U*@84V$E3W S)M!.Y! MIV(6=NZQZ [$VB8P=Z8D"4RR!K]Q\V0?^U104K2)'&_+W,!7J8"Z5,#.=,/- M>SC#N:T]1HL78*9;:E@TG^;%T!'^P6E8+CK"4KL^H%Y8?CTHV+']*O/>NQ1W MO0^]3' +T.]GY"%/544]:(!+X@V&+A#(TED/D@*F(BKMJ[XE+E.I,,GS"5IE MG3H&P1D?OI*A20V-1C_ZQ'5409(1'6P;; WT0WFJQ25Q/4\9QZR[IK*8:SHA MY3E3)%5OYT\K:P@@OJ+Y,@9MF_8F.&&>XU(_B/*&@)5&.48-0B E:RK:F'HR MS2 P'*45P&\@I$61@IBFD -T4J=.@T7@ND)_ ='U&LI8M&(XX($#)V2QQ"?X M@<[/]<BW(U$IE+='$XUG\"SX(8 @^'J8]FHH67+8Z#B2=/3,"/!7<43QC@ MR:>;3E0&[/]LM=!YGU$ERYO>VR*UN4K"MN,V6.O+7C#/T0Q2C.-$B*DUQC2W M1K>"06#FZ'UV@<5V,\>!O59%#,%)@1%RH:'KL1Z>PS+PI8@1YYPJ%H[LS0#R Mʚ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

UO^Z MTE=02P,$% @ +%!P4;ZW'ROX @ )PD !D !X;"]W;W)K&ULK99M;YLP$,>_BL6JJ96F\! 2TBZ)U#9-MVG5JF;=7COA M"*C&9K;)@[0/OS-0E"=07NQ-8L/]?[[SV7<,UT*^J1A DTW*N!I9L=;9C6VK M10PI51V1 <X[3MU.:<&L\+)X]R_%0Y)HE')XE M47F:4KF] R;6(\NUWA^\),M8FP?V>)C1) >&#,@=.-/Q;3J M)8UP=_Q.GQ:Q8RQSJN!>L-])J..1-;!("!'-F7X1ZR]0Q=,SO(5@JO@EZ]+6 M[UIDD2LMTDJ,'J0)+__IIMJ''8'G- B\2N ="-RF%;J5H'NX@ML@\"N!?ZZ@ M5PEZYPKZE:!_&$/0( @J05 DJ]S=(C43JNEX*,6:2&.--#,H\ENH,2,)-R=Q MIB6^35"GQ]\!\ZC(Y00T39BZ(A1G+')%>:B&ML9%C*F]J(!W)=!K #[1 M+>FZGXCGN(/7V81<7ER=@-R?#SFAGK2KOU'>.<.'AW;*##*D.(;B.4X85DVL\U@N6APE? MXO7A6&2-;R2"P_#+,UYB^P76%//5&$O[T%[M!G%LX^_8[/G;J_WMM?I[1_D; M6>944J[1,Y))L4I""(D69IR!U%LBUASDJ5TMV;T=A]PFA_JU0_U6AUY :9DO M="[-QL$&&^#1@2D7[Q_OF!_L[]C#L4UPO6\R/6'B7Y^.(:AC"-H/ 79H(B+" ML*"1O^3T]2EO87"T@UYC3@?U\H,SKH8R*:RNAHZ!,'/S3A7&=EA$V:&L=,K> M:0'F$^*)RF6"JS*($.1T @Q*EFVYG&B1%5UA+C3VF&(8XY<,2&. [R,A]/O$ M-)KZVVC\#U!+ P04 " L4'!1#^6G.S(" (!0 &0 'AL+W=OMD#K*LW!V;_/,;$E)C?<6 MW+9MA7U?HC*[>32)]@(%H<*"/(/@Y17O4"E/Q#)^#YS1&-(# M#_=[]F\A=\[E63B\,^I)EM3,HR\1E%B)K:('L_N.0SY!8&&4"U_8];ZS603% MUI%I!S K:*7N5_$VU.$ D$X^ *0#( VZ^T!!Y4J0R#-K=F"]-[/Y34@UH%F< MU/ZG;,CRK60+RN2PF#N=!<3%0 M+WOJ] /J":R-IL;!5UUB^2\^9IFCUG2O=9F>)-Q@=PG3Y!.DR>3F<;."\[.+ M$[33L0330#O]WQ*&PO=V]R:W-H965T_9 :@T&.1,SGS,J5V-[XODPP*(J_Y#IA^ ML^&B($H/Q=:7.P$DM: B]W$0#/V"4.;-IW;N3LRGO%0Y97 GD"R+@H@_"\CY M?N:%WF%B1;>9,A/^?+HC6UB#^KZ[$WKD-RPI+8!)RAD2L)EY[\*;);8 N^(' MA;T\>D8FE7O.?YG!IW3F!28BR"%1AH+HOP=80IX;)AW'[YK4:S0-\/CYP/[! M)J^3N2<2ECS_25.5S;RQAU+8D#)7*[[_"'5"L>%+>"[M+]I7:P<3#R6E5+RH MP3J"@K+JGSS6&W$$T#S= %P#\*6 J 9$-M$J,IO6+5%D/A5\CX19K=G,@]T; MB];94&:.<:V$?DLU3LU7()4H$U4*RK;H]2TH0G/Y!EVA[^M;]/K5&_0*48:^ M9;R4A*5RZBNM:K!^4BLL*@7XN$KA)95LCX2&\TF'3+ M#1NYH5/NCM 4<8$2SK0'=5?6\$SV*@JCGCQ'C?#(*;S,N71O[V)TOKU'JE5L MH[/8<%]DXR:RL3NRU=>WVAQ8N2&'&ZWO+.(J Z$]-R?*>8$FC&1 89/+ML:>BP9!WV*N%7$SZ[K_U9KV/I2&+],O;;6$[J]Y[)Z M/7>?*!KV;%%K/J';?2XHGD5X[C]Q$/Q[@N<&=-4?7VM!H=N#/I"$YE11D-9[ M/@,YNUNGS*WKA"]C.[BU'>RV'=?5QQUN,QAU[PYNS0:[S>:2JU]3#$^N_IFT M?]3S%2"VMA66FKADJFK_FMFFW7YGFTR_75[UZE^(T.4L40X;#0VN1SII4;6_ MU4#QG>T@[[G2_:A]S/0G PBS0+_?<*X. R/0?(3,_P)02P,$% @ +%!P M4<]KLN.( @ H@< !D !X;"]W;W)K&ULO55= M;]HP%/TK5M2'5AHD))!"!9%6HFF5-JV"=7N8]N F%V+5L3/; ?;O=^VD$6N! M=9O4!X@_[CGGWN.OZ5:J!UT &+(KN= SKS"FNO)]G1504MV7%0B<64E54H-= MM?9UI8#F#E1R/PR"V"\I$UXR=6.W*IG*VG FX%8179R2'%:VY6VCK&5F^3'+M_LFVB8T#CV2U-K)LP9A!R43SI;O6 MASW 8'@$$+: \*6 J 5$+P4,6\#0.=.4XGQ(J:')5,DM438:V6S#F>G06#X3 M=MF71N$L0YQ)%J"!JJP@5.3HUP;W086K:LAY"H8RKB](C]PM4W)^=D'."!/D M/)C8%2?S^A%G5JD5,; M'LU^ XJ*# CL\,QK.&1 0Q$["GO@-TDO&D3CJ;\YH#SLE(=Y.@5K(T[M?BO"LQ0[^#NCI_9.PBBH'.W MV<-_"/HMP\LNP\N7+7YO 9P:R$]4/>XXQZ_@\:13F_SW]IU/GEDW"I[8FSZ/ MZ451_,1>?^]"M*_71ZK63&C"886PH'^)VT\U+T+3,;)R=^2]-'CCNF:!CR@H M&X#S*RG-8\=>N]VSG/P"4$L#!!0 ( "Q0<%$<^;(1GP0 /40 9 M>&PO=V]R:W-H965T'AZ1& M6R'OU8HQC1ZS-%=G@Y76ZS>VK>(5RZBRQ)KE\&8I9$8UW,H[6ZTEHTD1E*4V M<9S SBC/!^-1\6PFQR.QT2G/V4PBM*"VR*A@89#PO_^EC58B] M !)V!) J@!P$N%T!;A7@'F;HHN15 =Y! /8Z OPJP#_,T!405 '!2P/"*B L M!JNL;C$T4ZKI>"3%%DG3&M#,13&^132,",^-%.=:PEL.<7H\7U')5B)-F%2_ MHLO/&ZZ?T&^(.'B(9IM%RF,DEDLF>7Z':)Z8%Q&:2?Y -4.SE,8,=*G1\91I MRE-U@HZ0C90!58CGZ";G6IW"0[A^S],4U*=&M@;B)KT=5R0O2I*D@^056U@( M>Z<%K9OY%!T?G90Y6K F_5A_;'(+N4Z!%558#>=.U&D_ZIRM=ZC$Z02Y[ >9 MLAA <$FM)?SJ.WKVRT^1&Y#?ZXZUP+W]#KBC#B ;Y%9KCM2:(P6RVU4LFC+T M88GF6L3WZ)\_X36ZUBQ3__: NS6X6X!['>!_;;(%DR!:)&3"<[#7G1PE [-6 MH%:6H,438C1>H?/I'!V#-LLF)VT#7Z;SBW3&V!_&_LA^:&'HU0R]7H9M-#+^1KF,:NWYHSI_]+^JZR)ZJ;J&-F8RYHHN4M9+!S\@$Q E=MXM,XX>8O+Y,.WJME,CS M^A />T'00:EQ4=QOH^WK?(^3X,;^L/?CC0HW-HC]%Q:S'MA.Y4\JK*]\(L0N M]H<=!6P,$_<[YBOFX:2"_,H-AH$31F$'F\8V<;]OSJ2(&4L46DJ1%0QH'C/# MKB+5[N&3"G;?Q FQNHK3N"CNM]%BUXG6D@.'-52I(&$X].U7)A7H<']%L2*/ M=+!I'!/W6^8,ICV(&TY>IB"T<8:25CE>IT@+M&!P=H(I*DN3WPG,:F7;GS1R M+,?YN6\WU;@LZ7?9VY+&SK]VA?V"CNO:MJT]5Q6L,=D]>[6:>I;;Q*I9N-?* ML]R.JI/&@4F_ ]^VV*X1 Q=M<^/R&V@^>F)4]NY.][:G_7;\:04"-&G M#&/%RXW>@" :6123J*AVV\[Q&VD\8D5!JP+LO?.<^2#PGLH[GBN4LB4@.58( M#B'+,W9YH\6Z..(MA(8#8W&Y8A3.=*8!O%\*H7L&X"M7 @ A04 !D !X;"]W;W)K&ULE53;;MLP#/T5PBBP%ECKQ$G\G MR8F7;6F&OL0B11X>'H5,5DJ_F1*18%T):49!2;2X#D.3E5@QEE,M+7"%B7G%4K#E02-Q2BXZ5Z/8Q?O WYP7)F],[A. M9DJ].>,Q'P4=1P@%9N00F/TL\1:%<$"6QOL6,VA+NL3]\P[]P?=N>YDQ@[=* MO/*<>(I8E6*] NVJ*Y@V_59UMR7+I'F9*VM]SF43HM MF<92B1RU^0+W[S6G#9S#*].:23*-:LYW>H?$N#!G< )B#DA$\*4FE@7N98_YG?FCIMSU$NQ[&T5' !YQ=0+?_%:).]^IE M>@>G)V='8'NM-#T/V_N$-$=@^RULW\/V/V++N(8E$S4"(Z 2889S+B67&ULQ59=3]LP%/TK5]&D@<22.$UI MB]I*@X+&!!IJ!WN8]N FMXW5) ZVT\*T'S\[":&4)N)A$WUH_''/\;GW)+:' M&RY6,D)4\)#$J1Q9D5+9B>/((,*$2IMGF.J9!1<)5;HKEH[,!-*P "6QX[GN ML9-0EEKC83%V(\9#GJN8I7@C0.9)0L7C*<9\,[*(]30P9H M;K,;H7M.S1*R!%/)> H"%R/K,SDY)YX!%!%W##=RJPTFE3GG*].Y#$>6:Q1A MC($R%%0_UGB&<6R8M([[BM2JUS3 [?83^T61O$YF3B6>\?@'"U4TLOH6A+B@ M>:RF?/,%JX2ZAB_@L2S^85/%NA8$N50\J"KX!8:(UFVD4U2_0NEXL-2_* M3 D]RS1.C6<1%1CQ.$0A/\+Y?<[4(WR""\H$W-$X1Z!2OT29<54"7\"&"D%3 M)8&F(7@NZ<,4UQJ,,,MBIN!@@HJR6!X.':7UF5625Y$O,O#K#/S6#&:*!RO(! L0#FYGD\.6JG1KSNX[>G-< MJSANS6R"@JVIV8?ABM$YTU_GX]%K0=J@UC=\4JY"R';M[;[_TJ#S/5&>W=WO M3:_.H->:P93)%2P$(@BJL*4D_9JP_X[&#&H5@W]AS#XO!ONJ[ ]VO-@31>Q. M;[\9Q'T^*MQ6W7<\UJJ-VI8BD*V3A[RC&>1Y(R7>_[*C8GZQ@7D[9NR)\?L[ M5CA;![BYGUU3L63ZO(UQH4&NW=-H45YYRH[B67&FS[G2-X2B&>EK(@H3H.<7 MG*NGCKDFU!?/\5]02P,$% @ +%!P48@)Q-7+ P $ \ !D !X;"]W M;W)K&ULS5==;]LV%/TKA+!B&]!(HFSYH[ -)$Z* M%EC6(,:ZAV$/M'5M$9%$E:3L&-B/'TG)DIQ)C-N]Y,66*)[#<\A+7M[9@?$G M$0-(])PFF9@[L93Y!\\3FQA2(ER60Z:^;!E/B52O?.>)G .)#"A-O,#W1UY* M:.8L9J;M@2]FK) )S>"!(U&D*>''&TC88>Y@Y]3P2'>QU W>8I:3':Q _I$_ M')22)9E(ZOE6D3CVF!K:?3^P?C7EE9DT$+%GR)XUD/' D8 M]0 &%6!@C);*C*U;(LEBQMD!<=U;L>D',S<&K=S03"_C2G+UE2J<7*QBPB%F M201<_(SNOA54'M$5^D@H1WN2%(#8%BD5FR?$84 MQ$SC->P3= MTCV-((O0D4(2=2VD'>^[OO^N:X:_&W8F/ZSEAU:>N^=^ZZ%.&/"?I-9_+=QMN%6LL-6>U]/&8WQB&;J MVE*>Y)WYJF0:&R9]&=JKM<'AS-NW5Z6C%W;]0=WK7&?0Z PNV_3[?# 'EY=V^*/A&PJM)/MA^[G]/>(5= MX35^&5[_[:52R[ GO)JL@B],*[WA]4I"N"2\+J/ ?L6!@B&*R-$:9TV>P?;S M?64NK%_*"ZN-L3GH\>2-1%MS5&/[6?U[D:Z!F_NYN8"7@V[:XO3%5Z!_^B_E MY0AA*[Z"%\'EM6J+%/C.E%Q"#5-DLKR.UZUU67=MBID7[3>ZW#,U2T-3UHKW MA.^HTIG 5E'Z[ECIX67Y5;Y(EIL*9LVDJH?,8ZQ*5N"Z@_J^94R>7O0 =1&\ M^!=02P,$% @ +%!P4>4$(%N\ P CPP !D !X;"]W;W)K&ULK5=M;]HZ%/XK1]&DNTDKB9- P@1(+>UVK[1N55'O=#^: MY$"L)C:S#;3_?G:2!C:";Z_NOA"_/<]Y]?%ALA?R416(&IZJDJNI5VB]^>#[ M*BNPHFH@-LC-SDK(BFHSE6M?;232O 95I1\&P;%*OW M25#;JJ+R^0I+L9]ZQ'M9N&?K0ML%?S;9T#4N4#]L[J29^1U+SBKDB@D.$E=3 M[Y)\F)/$ NH3?S/&+.D"N>B_,9R74R]U(,<5W1;ZGNQ_Q-;@X:6+Q.EJG]A MWYX-/,BV2HNJ!1L-*L:;+WUJ'7$$"$=G &$+"'\!&,_T Z(6$-6&-IK59EU3 M36<3*?8@[6G#9@>U;VJTL89Q&\:%EF:7&9R>+0HJL1!ECE+] 3??MTP_PP4L MFJB"6(&)O=*4YXROP7P GU!F3-%EB2 V-A8*WEZCIJQ4[RQ4B^P1OK8[%Q & MA("R8MKCL"DI-QL/BVMX^^8=O &_V5? .#QPIM5[LVC&MZPL+_!S-YZ$#@+?^+AS=/CBZ*O0R;C S0"BX+WQ M1QCT*>2&7V-FX,3"R=BA3M3%/:KY(E?<+^P%R"$3E:D*BMK@.*CCCCJNJ>,S MU)?KM<0UU6A"J"4S-SZ#'2VWV!?&AFI44]F2LYL9Y^QZI \[Z4.G85^VU1)E MG;A-"CHL&G6<(Z=%7X^O@ 9=("QQS3@W"WU&-6S#(Z.B- RC).XW+>G42)QJ M?)*4Z]YLODI.)*;I, C.^#+M!*9.@:90KI"=$9F>B+P@PR0-(M(O=-P)'?]7 M9R/OU6!\ZF82CJ,XZA1H;E;/.5\D M'>[1=G+69W/SFDG3,VUI"9_9RM9F^ >I=)5':538(Z P MYPH !D !X;"]W;W)K&ULS59=;]HP%/TK5C1I MK=0V7Q"@ B0*;*NT:JBLV\.T!S>Y$*M.G-H&VOWZV4Y((:01VOK0%["=<\[] M3'S[&\8?1 P@T5-"4S&P8BFS2]L680P)%A8*FV?&F+C ..#"FA MMN4MVWR!(J"VU@L9%>87;0JL8Z%P)21+"K+R("%I_H^?BD3L$)1./<$K M"%Z5T'J%X!<$_U@+K8+0.M9"NR"8T.T\=I.X"99XV.=L@[A&*S6],-DW;)4O MDNI&F4NNGA+%D\-YC#G$C$; Q4.VC&Y;*6*!I&D%4PY\T\WL-?%MEL$RCMTWC ME=@GS/V\=,:H1ZP3YF>HAQ MG8Y3@O:B;I=1MQNCO@4!F(>QR7($:W4I9*86]5'OV0A*&\'[*'6G=*CS]J7. M)=N[%?)Z3J74AR"WW:J4ND;(#:JU/@2U_&Y]J;MEU-W&J#]#"AQ3DV0SEV:\XG>HHS@\*+?#X" MWF"^).I2IK!0IIR+CFI(GD]5^4:RS(P-]TRJ(<0L8S6) M< ]7S!F-QNM(%R MMAW^!5!+ P04 " L4'!1H8M:>;4" !D!P &0 'AL+W=OYB0B#_N.3[7Q[X>;91^-#FBA:="2#,.J1$DS2Z4+9JFK5Z$I-;+,@PH1QE%T&A:,RV R\F-S/1FIR@HN M<:[!5$7!]/,4A=J,@TZP';CCJ]RZ@7 R*MD*%VB_EW--O;!ER7B!TG E0>-R M')QWSF8#%^\#?G#E'ITG>ML'$1.$ I,K6-@]%GC#(5P1"3C=\,9 MM$LZX&Y[RW[EJ/_8=/$ M1@&DE;&J:,"DH."R_K*G9A]V ,2S'Q W@/@MH'L D#2 Q"=:*_-I73#+)B.M M-J!=-+&YAM\;CZ9LN'0N+JRF64XX._E*!^5&&0,EDK69UQ4;L_!8%II;CD:^'"!EG%A/A+*H\THM"3+D8=I(V%:2X@/2!C" MK9(V-W I,\Q>XT-*I\TIWN8TC8\2+K \@23Z!'$41WOTS-X-[PR/R$G:+4X\ M7_<0GU7I(WPKW;$U1_BZ+5_7\R4'^%YYL7CQXO(I%17M("RU*F"FBK*RS-\5 MM81+IB67*P-S\GGA??YY0\1P;;$POX[(ZK6R>D?3/"!KWWFHB7J>R)69]23I MQ,.DFXS"]:Y/>^*&@Q[]VKA72D];I:='E5Z@YFOF=5YQ2>><,P'7TEA=47VR MAL[R/=-T >PQN_KM:OW_R:Y!*VOPK^P:_&5#)QKV>\/>\(U?[PBLM88[!:M MO?)UW$"J*FGK>]Z.MD_%N:^0;\:G](34%?^%IGY_;IE><6E X)(HHY,^R=)U M3:\[5I6^+#XH2T76-W-Z!E&[ )I?*F6W';= ^[!._@!02P,$% @ +%!P M469:6BQ< @ @@P T !X;"]S='EL97,N>&ULU5?=;ILP%'X5RYFF5II* M($O:KH"T5:HT:9LJ-1>[JPP8L.0?9DQ&>KG'V6/M269C B0-5=2++;F)S_F. MSW<^VX=@_%*M*7[(,5:@9I27 (+P_3 M_*+H4?*K_>1_?OT>WY(^N+TI3GNPH9\*WI_O#%I UT<,@Q6B ;Q%E$22F*P4 M,4+7%O8,$ LJ)%"ZL;0@UR#EDPV[UC,]U_(PPH5L:ML*]C=JI^\$-IX12"CM M!'K0 J%?(*6PY'?::28WX+,0:.WENM *,XG6KC>'?4(SZ"*1D F671D7;J#0 MIS@UR._I%G>=#DYV:LZ5 M=Z86U)J6QCJ&?\AFN8>TWJMX04%60GVJ]')XXYMFP?<2IZ1N_#KM!(RQN^/L MJ"CH^B,E&6?8+O[@@J&/-GD@%Y(\Z6JF56(-8 G!"DM%XB'R4Z)BB6NU::98(CH4K7O_F'?YU8IGE_]+G(')Q M"B)/HB>OCE_D[/HH-3KM^WMP2=BZ(G0H,%>Q 'XS5S_:%P511:@BO/5RDB28 M/[LI:'J%(OU!L,6OYRMNUKW9B'96;W\QRW,73<'^ MJR/\"U!+ P04 " L4'!1EXJ[', 3 @ "P %]R96QS+RYR96QS MG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2 MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N M&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,E MC'%BM/XU@LD/['X 4$L#!!0 ( "Q0<%'L0I1X; , -,7 / >&PO M=V]R:V)O;VLN>&ULQ9C?;]HP$(#_%2LOVQXZB--V:U4J4:!;)4:K!76/DTF. MQJIC,]OIK[]^ES TL]+37BR>$CO&^7+$]UU\]FCL_<*8>_94*^T&2>7]ZK37 MMMD#]+)A532/P^2[EQ!PFJI92U?H!PD_82YRCQ^-5:^ M&.V%R@MKE!HDZ?K"+5@OBU?=>0LY%PO7]7BQ^"X09) <]W'"I;3.=R.Z^04R M/@ .7K<:;RZE\F#'PL,7:YJ5U'?M-/@4O> QNCALCNL@GMK_":-9+F4!8U,T M-6B_CJ,%U0)J5\F52Y@6-0R2S1 F=,DFVF.0V)5>3X5CVR?%6U^5ZZ?VB!O$ MT)Y*O&"OR@X\'N3H>C:>S/+)F.%9?CV]&@_GV+@83H>ST80%D)R Y'N$_,D# MR(R S/8"F<_Q\&TR"R /"Y#6$=3?N"1_;!KA>R$I!3!(ROB]5+9B4A^D$3V!EFS;*T9 M3EF$1[8(M6;&$.9M3GF%1_;*NB;HD(14V_\RY1,>V2>OJH/=B)16>&2M_)-N M=N%1;N&1W?)6Q?"'-,2DW,(CNV5G6CQ@O)^>L)LF= NGW,)C?X3LQOPAK$5C MAT5U1DDFVX=D#MBED);="A5B4IK)(FN&PGS8WE6B5)-%5LT;F)NJ+<0D=[\B MJ^8MS+;[8"%"3$HU6635[*@M$!(3$ZZ@ K:B29DGZ\S3VVPBE["4&LH9WL)A M?R%4<6-9>UA_X1X>M37ILE%JA'W7>FI$N=F3WNRGG_\&4$L#!!0 ( "Q0 M<%%+BJ +&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/- MV$UNPC 0AN&K1#X SLSP6P&K;MA67" *AB#RI]A5X?:-PB)\41?=(,\J1=Y^N3(+UZ;VQ;7UR;TJ:[\S10CMA[4^+UR5^5G3NKI_%$QL8.8@CB^$$"01(_: Y!\_A!"PA: MQ ]:0M R?M *@E;Q@]80M(X?M(&@3?P@2E'&5$'2!&L%6A-R30J\)@2;%(A- M2#8I,)L0;5*@-B';I,!M0KA)@=R$=),"NPGQ)@5Z,^K-"O1FU)L5Z,V3GVT% M>C/JS0KT9M2;%>C-J#K$!O1KU9@=Z,>K,"O07U%@5Z"^HM M"O06U%L4Z"V3PQ(%>@OJ+0KT%M1;WJFW#X_2^;'GN<;]WTEUZ-]UX_;#\GES M\D$-.%LX8-W_ E!+ P04 " L4'!1WR$G&Y(! #Y%0 $P %M#;VYT M96YT7U1Y<&5S72YX;6S-F,UNPC 0A%\ERA418Z>E/P(N;:\MA[Z FVR(11); MMJ'P]G7"C]2*1B J=2ZQ$N_.C+W2=\CD?6O(19NZ:MPT+KTWCXRYK*1:ND0; M:L).H6TM?7BU"V9DMI0+8F(T&K-,-YX:/_2M1CR;/%,A5Y6/7C;ALU.ZF<:6 M*A='3[O"UFL:2V,JE4D?]MFZR7^X#/<.2>CL:ERIC!N$@IB==&AW?C?8][VM MR5J54S27UK_*.E2Q3<6&UL4$L! A0#% @ +%!P44 D(ADM! M$@\ !@ ("!#0@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +%!P46:B=$S_ P 60T !@ M ("!+!0 'AL+W=O9/9EJ04 . ; 8 " @6$8 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ +%!P40BD@#A3!0 $Q0 !@ ("!D" 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ +%!P4=)8&?GP P MK@D !D ("!_C@ 'AL+W=O&PO=V]R:W-H965T4_ !X;"]W;W)K&UL4$L! A0#% @ +%!P48FS9O3"!0 . T !D M ("!=T0 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ +%!P4?\R$".."P ,1X !D ("!\U, 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +%!P M46)D\GN- @ DP4 !D ("!36< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +%!P46#[=U5W @ 0 4 M !D ("!-G( 'AL+W=O&UL4$L! A0#% @ +%!P4;ZW'ROX @ )PD !D M ("!#GL 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ +%!P4<]KLN.( @ H@< !D ("!(X0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ +%!P43P= M]N<: P A H !D ("!1HX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +%!P4>:538(Z P YPH !D M ("!C)D 'AL+W=O;4" !D!P &0 @(']G >&PO M=V]R:W-H965TF? !X;"]S='EL97,N>&UL4$L! A0#% M @ +%!P49>*NQS $P( L ( !<*( %]R96QS+RYR M96QS4$L! A0#% @ +%!P4>Q"E'AL P TQ< \ ( ! M6:, 'AL+W=O7!E&UL4$L%!@ K "L I L &"J $! end
XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 111 233 1 false 21 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.anchiano.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.anchiano.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.anchiano.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://www.anchiano.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 5 false false R6.htm 00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) Sheet http://www.anchiano.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.anchiano.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.anchiano.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 8 false false R9.htm 10101 - Disclosure - The Company and Basis of Presentation Sheet http://www.anchiano.com/role/DisclosureCompanyAndBasisOfPresentation The Company and Basis of Presentation Notes 9 false false R10.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.anchiano.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10301 - Disclosure - Accrued expenses and other Sheet http://www.anchiano.com/role/DisclosureAccruedExpensesAndOther Accrued expenses and other Notes 11 false false R12.htm 10401 - Disclosure - Leases Sheet http://www.anchiano.com/role/DisclosureLeases Leases Notes 12 false false R13.htm 10501 - Disclosure - License Agreement Sheet http://www.anchiano.com/role/DisclosureLicenseAgreement License Agreement Notes 13 false false R14.htm 10601 - Disclosure - Restructuring Sheet http://www.anchiano.com/role/DisclosureRestructuring Restructuring Notes 14 false false R15.htm 10701 - Disclosure - Research and development Sheet http://www.anchiano.com/role/DisclosureResearchAndDevelopment Research and development Notes 15 false false R16.htm 10801 - Disclosure - Shareholders' Equity Sheet http://www.anchiano.com/role/DisclosureShareholdersEquity Shareholders' Equity Notes 16 false false R17.htm 10901 - Disclosure - Net Loss per share Sheet http://www.anchiano.com/role/DisclosureNetLossPerShare Net Loss per share Notes 17 false false R18.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.anchiano.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.anchiano.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30303 - Disclosure - Accrued expenses and other (Tables) Sheet http://www.anchiano.com/role/DisclosureAccruedExpensesAndOtherTables Accrued expenses and other (Tables) Tables http://www.anchiano.com/role/DisclosureAccruedExpensesAndOther 19 false false R20.htm 30603 - Disclosure - Restructuring (Tables) Sheet http://www.anchiano.com/role/DisclosureRestructuringTables Restructuring (Tables) Tables http://www.anchiano.com/role/DisclosureRestructuring 20 false false R21.htm 30803 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.anchiano.com/role/DisclosureShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.anchiano.com/role/DisclosureShareholdersEquity 21 false false R22.htm 30903 - Disclosure - Net Loss per share (Tables) Sheet http://www.anchiano.com/role/DisclosureNetLossPerShareTables Net Loss per share (Tables) Tables http://www.anchiano.com/role/DisclosureNetLossPerShare 22 false false R23.htm 40101 - Disclosure - The Company and Basis of Presentation (Details) Sheet http://www.anchiano.com/role/DisclosureCompanyAndBasisOfPresentationDetails The Company and Basis of Presentation (Details) Details http://www.anchiano.com/role/DisclosureCompanyAndBasisOfPresentation 23 false false R24.htm 40301 - Disclosure - Accrued expenses and other (Details) Sheet http://www.anchiano.com/role/DisclosureAccruedExpensesAndOtherDetails Accrued expenses and other (Details) Details http://www.anchiano.com/role/DisclosureAccruedExpensesAndOtherTables 24 false false R25.htm 40401 - Disclosure - Leases (Details) Sheet http://www.anchiano.com/role/DisclosureLeasesDetails Leases (Details) Details http://www.anchiano.com/role/DisclosureLeases 25 false false R26.htm 40501 - Disclosure - License Agreement (Details) Sheet http://www.anchiano.com/role/DisclosureLicenseAgreementDetails License Agreement (Details) Details http://www.anchiano.com/role/DisclosureLicenseAgreement 26 false false R27.htm 40601 - Disclosure - Restructuring (Details) Sheet http://www.anchiano.com/role/DisclosureRestructuringDetails Restructuring (Details) Details http://www.anchiano.com/role/DisclosureRestructuringTables 27 false false R28.htm 40701 - Disclosure - Research and development (Details) Sheet http://www.anchiano.com/role/DisclosureResearchAndDevelopmentDetails Research and development (Details) Details http://www.anchiano.com/role/DisclosureResearchAndDevelopment 28 false false R29.htm 40801 - Disclosure - Shareholders' Equity - 2019 Public offering and 2018 Private Placement (Details) Sheet http://www.anchiano.com/role/DisclosureShareholdersEquity2019PublicOfferingAnd2018PrivatePlacementDetails Shareholders' Equity - 2019 Public offering and 2018 Private Placement (Details) Details 29 false false R30.htm 40802 - Disclosure - Shareholders' Equity - Warrants activity (Details) Sheet http://www.anchiano.com/role/DisclosureShareholdersEquityWarrantsActivityDetails Shareholders' Equity - Warrants activity (Details) Details 30 false false R31.htm 40803 - Disclosure - Shareholders' Equity - Fair Value assumptions of warrants and 2018 Reverse Split (Details) Sheet http://www.anchiano.com/role/DisclosureShareholdersEquityFairValueAssumptionsOfWarrantsAnd2018ReverseSplitDetails Shareholders' Equity - Fair Value assumptions of warrants and 2018 Reverse Split (Details) Details 31 false false R32.htm 40804 - Disclosure - Shareholders' Equity - Fair value of stock options (Details) Sheet http://www.anchiano.com/role/DisclosureShareholdersEquityFairValueOfStockOptionsDetails Shareholders' Equity - Fair value of stock options (Details) Details 32 false false R33.htm 40805 - Disclosure - Shareholders' Equity - Summary of outstanding and exercisable options (Details) Sheet http://www.anchiano.com/role/DisclosureShareholdersEquitySummaryOfOutstandingAndExercisableOptionsDetails Shareholders' Equity - Summary of outstanding and exercisable options (Details) Details 33 false false R34.htm 40806 - Disclosure - Shareholders' Equity - Share-based compensation expenses (Details) Sheet http://www.anchiano.com/role/DisclosureShareholdersEquityShareBasedCompensationExpensesDetails Shareholders' Equity - Share-based compensation expenses (Details) Details 34 false false R35.htm 40901 - Disclosure - Net Loss per share - Severance pay and Antidilutive securities (Details) Sheet http://www.anchiano.com/role/DisclosureNetLossPerShareSeverancePayAndAntidilutiveSecuritiesDetails Net Loss per share - Severance pay and Antidilutive securities (Details) Details 35 false false All Reports Book All Reports ancn-20200930.xml ancn-20200930.xsd ancn-20200930_cal.xml ancn-20200930_def.xml ancn-20200930_lab.xml ancn-20200930_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 52 0001104659-20-125523-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-125523-xbrl.zip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end